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     Type 1 diabetes (T1D), a disease characterized by the autoimmune-mediated 
destruction of the insulin-secreting beta cells of the pancreas, affects approximately 1% of the 
US population, with an incidence that is increasing at a rate of 3% per year.  Beta cell killing is 
accomplished through various immune-mediated mechanisms, with the production of reactive 
oxygen species (ROS) contributing to both inflammation and cell death.  While previous reports 
suggested that antioxidant scavenging protected beta cells against ROS-mediated damage, islet-
specific over-expression of antioxidants was not fully protective.  As systemic elevation in free 
radical defenses had a positive impact on islet survival, I hypothesize that control of oxidative 
stress at the level of the immune system will regulate proinflammatory responses. 
     Genetic studies using the ALR mouse have provided strong support for my 
hypothesis.  ALR-derived diabetes resistance and reduced oxidative burst from neutrophils and 
macrophages, as well as elevated Superoxide Dismutase 1 (SOD1) activity all map to the 
Suppressor of superoxide production (Susp) locus on Chr. 3.  NAPDH oxidase (NOX) function 
from ALR cells could be rescued with inhibition of SOD1, demonstrating that dissipation was 
modifying immune effector function.  Elevated SOD1 activity was associated with increased 
dimer stability, suggesting a post-translational modification is enhancing dimerization.   
     Introduction of Susp into the NOD background was highly protective against T1D.  
This resistance is linked to the loss of T lymphocyte diabetogenic potential.  The loss of T cell 
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ROS in T1D protection was confirmed using NOX-deficient NOD mice.  T cell lineage 
commitment and proinflammatory cytokine synthesis were dependent on ROS signaling.  
Macrophages and T cells from NOD-Ncf1m1J mice exhibited a skewed cytokine response, with 
increased synthesis of IL-17 and IL-10, as opposed to the predominant IFN-γ production 
typically observed from NOD lymphocytes. 
     Genome-wide analyses were performed to fine map Susp in order to define the 
mechanism leading to altered SOD1 activity.  Positional cloning experiments mapped Susp 
between D3Mit180 (34.4 Mbp) and D3Mit223 (34.8 Mbp) on Chr. 3.   This mapping defines a 
novel candidate region involved in the regulation of SOD1 activity and dimerization stability, 
resulting in reduced superoxide release via NADPH oxidase activity. 
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1.0  INTRODUCTION 
The pancreas has important functions in the digestive and endocrine systems through the 
release of digestive enzymes and hormones, respectively.  The hormone synthesizing cells, 
including insulin-producing beta cells, are organized within the islets of Langerhans along with 
glucagon-producing alpha cells, somatostatin-secreting delta, and pancreatic polypeptide-
secreting gamma cells.  Human islets are composed predominantly of alpha and beta cells, in 
similar number, whereas rodent islets contain mostly beta cells.  The main function of the 
pancreatic islets is the regulation of blood glucose, and insulin plays a major role in this process.  
Insulin, a 6 Kd hormone composed of two chains linked by disulfide bridges, is secreted in 
response to rising concentrations of glucose in the blood.  As glucose concentrations rise in the 
blood, they also increase in the interstitial fluid, leading to glucose transport into the beta cells 
via Glucose Transporter 2 (Glut2).  Catabolism of glucose metabolism inside the beta cell 
increases the ATP/ADP ratio.  To adjust to this increase in ATP, potassium channels close, 
depolarizing the plasma membrane and in turn opening calcium channels.  Calcium flux then 
allows for the fusion of secretory granules with the plasma membrane, releasing insulin into 
circulation (1-3).  Once in circulation, insulin signals for the uptake of glucose by muscle and fat 
cells.  The binding of insulin to the insulin receptor initiates a signal cascade, which includes 
translocation of Glucose Transporter 4 (Glut4) to the membrane of muscle cells and adipocytes 
to facilitate glucose uptake.  In conditions where there is a lack of insulin or improper signaling 
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from the insulin receptor, glucose uptake and metabolism are not regulated, resulting in 
hyperglycemia and overt diabetes.   
1.1 TYPE 1 DIABETES 
1.1.1 Autoimmune pathogenesis 
Diabetes Mellitus is a collection of syndromes characterized by the inability to regulate 
blood glucose, resulting from any dysfunction in insulin processing, secretion, and/or signaling.  
Type 1A Diabetes (T1D), or juvenile diabetes, is an autoimmune disease characterized by the 
targeted destruction of insulin-producing beta cells, resulting in hyperglycemia, other metabolic 
disturbances, and dependency on exogenous insulin (4).  In animal models, leukocytic 
infiltration of the pancreatic islets is witnessed as part of the early stages of disease (5-7).  
Present within the insulitic infiltration are macrophages, dendritic cells, T cell subsets and B 
cells; these cell types are implicated in the autoimmune process and associated complications in 
varying capacity. 
Critical information has been derived from the study of organs procured from deceased 
human T1D patients.  The insulitic infiltrates of cadaveric pancreata demonstrate the presence of 
CD8+ cytotoxic T lymphocytes, macrophages, B cells, and CD4+ helper T cells (7).  In recent 
onset cases in which insulitis was present, infiltrates affected insulin-positive islets as opposed to 
insulin-deficient endocrine clusters (8).  Analysis of beta and alpha cells shows only significant 
decreases of beta cells, with persisting insulitis and increased expression of MHC I and Fas (9).  
These data support the hypothesis that specific immune reactivity to beta cell antigens is central 
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to diabetes progression.  However, even with newer programs, such as the Network for 
Pancreatic Organ Donors with Diabetes (nPOD), human samples have been scarce; therefore, 
much of the knowledge delineating the pathogenesis of T1D has been extrapolated from studies 
using NOD mice. 
1.1.2 Mouse Model: Non-obese Diabetic 
Animal models have been fundamental to T1D research.  Mouse models, specifically the 
autoimmune diabetes-prone Non-obese Diabetic (NOD) mouse, have played an increasing role in 
the discovery of disease mechanisms, identification of autoantigens, and the development of a 
better understanding of the genetic pathogenesis of T1D. 
The NOD strain was originally outbred from the Jc1:ICR mouse line during the selection 
of a cataract-prone strain with high fasting blood glucose.  During this process, a female mouse 
spontaneously developed diabetes.  Inbreeding of the offspring proceeded, developing a sub-line 
that developed a spontaneous diabetic condition (10, 11).  Diabetes onset in NOD female mice 
manifests between 12-24 weeks of age, with approximately 80% of the females developing the 
disease.  The NOD mouse strain is an extremely important animal model for T1D research, as 
this mouse stands as a surrogate for studies that are too invasive for clinical research. 
With its pathogenic and genetic similarities to the human condition, the NOD is a useful 
tool to study the etiology, pathology, and progression of disease.  While the NOD model is not 
without fault (12-14), the NOD is particularly useful in that it facilitates the isolation, study, and 
manipulation of specific genes, polymorphisms, and other genetic factors to identify not only 
how a specific gene may function deleteriously, but also to understand how specific 
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combinations of normal alleles result in immune dysregulation and autoimmune disease (12, 15-
17). 
1.1.3 Innate Immune System 
The first line of defense against infection is provided by cells of the innate immune 
system, based on pattern recognition.  Neutrophils, members of the polymorphonuclear (PMN) 
cell family that are distinguished by multi-lobed nuclei, are early responders to infection, as they 
are rapidly mobilized and activated (18).  Following chemotactic signals, including interleukin 
(IL)-8 and interferon (IFN)-γ, neutrophils migrate to the site of inflammation within the first 
hour of infection, making them early contributors to acute inflammation and host defense 
responses (19-21).  Antimicrobial functions of these cells involve phagocytosis followed by the 
release of reactive oxygen species (ROS) and hydrolytic enzymes (22).  Macrophages are also 
phagocytes; however, they also serve as important antigen presenting cells (APC).  
Macrophages, along with dendritic cells (DC) and B cells, present antigen to and recruit adaptive 
immune lymphocytes.  Through the secretion of cytokines and chemokines, these cells regulate 
the inflammatory processes (23-25).   
Innate immune cells, including DC and macrophages, are critical for initiating the process 
of beta cell death during T1D.  DC and macrophages are found in insulitic infiltrates and are 
implicated in driving early autoreactive immune responses (26).  The depletion of macrophages 
protects NOD mice from T1D and insulitis (27).  T cells from a macrophage-deficient 
environment lack diabetogenic potential, yet islet reactivity is restored when macrophages are 
replenished (28), demonstrating an essential role of macrophages in T1D development and 
pathogenesis.  As well, DCs are critical for the initiation of T cell responses or induction of 
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tolerance, depending on the DC subset and T cell requirement (29-31).  Antigen presentation by 
DC and macrophages provides antigen-specific activation of T cells (32, 33).  The activation 
status of the APC, ROS signaling, and cytokine/chemokine milieu at the site of infection are all 
proposed to dictate signaling and differentiation of T cells.  These factors determine the type of 
response: effector, pathogenic, or tolerogenic (33, 34).  Activated T cell effectors produce 
proinflammatory cytokines, which may also facilitate further recruitment and activation of 
macrophages and neutrophils.  These cytokines stimulate ROS production by macrophages, 
leading to the amplification of the inflammatory response subsequently mediated by adaptive 
immune cells (35, 36).  Therefore, complex interplay of the innate and adaptive immune systems 
can promote either pathogenic or tolerogenic responses.  These interactions are potential targets 
for therapies aimed at preventing T1D.  It has been proposed that T1D in the mouse and human 
develops due to a break in or lack of tolerance resulting from poor APC function.  Clinical trials 
are currently underway to investigate the safety and potential of DC therapy to promote tolerance 
or enhanced regulation of self-reactive T cells in human cohorts (37). 
1.1.4 Adaptive immune effectors 
Adaptive immune cells, specifically T lymphocytes, are implicated as the final effectors 
of beta cell death resulting in overt diabetes.  T cells recognize specific peptide antigens when 
presented in the context of Major Histocompatibility Complex (MHC) molecules.  This 
recognition is mediated by the T cell receptor (TCR).  TCR chains are generated through the 
recombination of T cell receptor genes using variable alleles, creating an estimated 109 possible 
rearrangements for the TCR during T cell development in the thymus.  This process of TCR gene 
recombination generates the immensely diverse repertoire needed to recognize and protect from 
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the variety of infections an individual may encounter.  However, with great diversity comes the 
potential for recognition of self-peptides.  During the maturation of T cells in the thymus, each 
cell undergoes positive and negative selection to MHC and antigen.  Defects in negative 
selection are proposed to provide significant contributions to T1D susceptibility and 
development (38-40).  Over 5,000 self-peptides are presented in the thymus, contributing to 
selection.  The autoimmune regulator (AIRE) controls the wide range of genes expressed in the 
thymus (36, 39) and mutations in AIRE are associated with various autoimmune conditions, 
including T1D (39-41).  Antigen is presented in the thymus and periphery in association with 
MHC.  Polymorphisms in MHC are strongly associated with susceptibility in human and murine 
autoimmunity.  As MHC molecules are important for T cell development and activation, the 
susceptibility or resistance alleles are proposed to influence thymic selection as well as tolerance 
in the periphery (36).   
T cell activation occurs in response to specific antigen presentation and co-stimulation 
through the engagement of MHC/TCR and B7/CD28, respectively.  Autoreactive responses of 
CD4+ and CD8+ T cells to islet antigen have been implicated in the pathogenesis of diabetes in 
humans and NOD mouse models.  Diabetic patients and first-degree relatives are screened for 
autoantibodies against islet beta cell antigens, including insulin, glutamic acid decarboxylase 
(GAD) 65, islet cell antigen (ICA) 69, and insulinoma-associated-2 (IA-2A).  The diabetogenic 
potential of these antigens has been established in NOD mice.  T cells from NOD mice respond 
to GAD65 (42, 43), demonstrating immune recognition and activation.  The injection of GAD65 
peptides can alter disease, depending on the site and timing of injection (44).  Vaccination with 
GAD65 peptides, proteins, and DNA encoding GAD65 reduces T1D incidence in NOD mice 
(45, 46).  However, GAD65-deficient NOD mice are not protected from disease, and NOD mice 
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over-expressing GAD65 in the pancreatic islets do not exhibit exacerbated disease (reviewed in 
(47)).  These data demonstrate the diabetogenic potential of GAD65, yet expression and 
reactivity is not essential, suggesting that it is one of several autoantigens. 
Insulin has also been studied and described as a significant autoantigen in T1D (reviewed 
in (48)).  T cells are present in islet infiltrates in the NOD and have been shown to react to the 
insulin B-chain (49).  Expression of insulin B-chain in the thymus can reduce T1D incidence 
(50), demonstrating a role for islet antigen expression during negative selection.  Additionally, 
knockout of Ins2 on a mixed 129/B6 background, which has a protective H2b MHC allele, was 
sufficient to induce anti-insulin autoimmunity (51).  Similarly, human patients with the 
susceptibility allele in the variable number tandem repeat (VNTR) element of the insulin gene 
promoter show decreased expression of insulin in the thymus and increased susceptibility to T1D 
(52, 53).  These data demonstrate both the importance of thymic selection and that a defect in 
elimination of autoreactive TCR contributes to T1D.  Increased thymic expression of insulin 
mRNA was linked with individuals that had protective alleles at the INS locus (52, 54).  Using 
genetically manipulated NOD mice, insulin expression in the thymus has been both increased 
and deleted, resulting in altered T cell insulin autoreactivity, demonstrating that the natural levels 
of thymic insulin expression are important in the development of the TCR repertoire.  Altered 
thymic INS expression in patients or animals models with T1D likely results in changes in the 
deletion of insulin-specific autoreactive T cells (55-57).  The specific knock out of insulin 
expression in the thymus induced diabetes in NOD background as early as 3 weeks of age, 
demonstrating a critical loss of tolerance resulting from a lack of negative selection (51).  
PTPN22, a negative regulator of T cell activation (58, 59), is associated with T1D (60, 61), as 
well as other autoimmune diseases (61, 62).  Studies using NOD congenics for PTPN22 
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orthologue, Ptpn8, showed modified incidence of T1D, demonstrating a role for PTPN22 in 
human and murine T1D (16).  
The recruitment and activation of T cells is dependent on the presentation of 
antigen/MHC complexes by APC.  Through the use of NOD TCR transgenic mice, the 
importance of antigen/MHC presentation to islet-specific T cells in the pancreatic lymph nodes 
(PLN) has been demonstrated (63).  It is proposed that initial beta cell damage releases 
autoantigens, which are then processed and presented to T cells in the PLN (64).  Antigen is 
proposed to be available between 15 and 18 days of age in the NOD (63, 64), which was 
associated with an increase in activated T cells (65).  Early removal of PLNs can protect from 
T1D development, whereas late removal does not alter the course of T1D (65), suggesting the 
importance of early recruitment and priming of diabetogenic T cells in the PLNs.  Islets express 
lymphocyte alpha4beta7 integrin and endothelial mucosal addressin cell adhesion molecule-1 
(MAdCAM-1) which are both important for lymphocyte trafficking to mucosal lymphoid tissues, 
including the pancreas (66).  The blockade of beta7 integrin or MAdCAM-1 with monoclonal 
antibodies significantly protected NOD mice from diabetes onset and insulitis, demonstrating a 
tissue-specific role for alpha4beta7 and MAdCAM-1 for lymphocyte migration to the pancreas 
(67). 
After activation and homing to the site of inflammation, the pancreatic islets, effector T 
cells amplify the immune response and mediate beta cell killing through various mechanisms.  
CD8+ T cell destruction of islets has been implicated in providing early release of antigen to 
prime and activate CD4+ T cells (68).  CD8+ Cytotoxic T cells (CTL) are present in pancreatic 
islets of both patients as well as NOD mice (69) and contribute to beta cell killing.  NOD mice 
deficient in perforin or Fas are both protected from T1D development, demonstrating that these 
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are two pathways by which CTLs mediate beta cell death (70, 71).  CD8+ T cells from NOD 
mice transgenic for the 8.3-TCRβ chain with or without perforin can kill target cells that express 
Fas (72).  In addition, islet grafts lacking Fas are also destroyed in NOD hosts (73).  T cells from 
8.3-NOD lacking perforin and/or Fas were able to mediate beta cell killing (74), demonstrating 
that CTLs have multiple cytotoxic mechanisms in their arsenal and will use any and all means 
necessary to accomplish beta cell killing.  
CD4+ T cells are involved in diabetes through the recruitment of CD8+ T cells and B 
cells, as well as cytokine production.  The accumulation of CD8+ T cells in NOD islets requires 
CD4+ T cells in 8.3-NOD mice (75).  Likewise, the adoptive transfer of CD8+ T cells alone does 
not transfer disease.  The transfer of CD4+ T cells from pre-diabetic donors is slower than 
transfer with diabetic donor cells, and pre-diabetic CD4+ T cells do not transfer disease when 
recipients are treated with anti-CD8-depleting antibodies (76).  These data highlight a role for 
exposure to beta cell antigen for diabetogenic potential, as well as the necessity of CD4+ and 
CD8+ T cells for disease initiation.  Priming of CD8+ T cells is provided by professional APC 
and not the beta cell.  NOD mice deficient in Class I MHC on APC do not develop diabetes, and 
insulitis does not progress (77).  B cells are recruited and activated to produce antibodies.  They 
also serve as important APC (reviewed in (78)).  The role of antibodies in the pathogenesis of 
T1D is not clear; titers are used to evaluate risk (79).  Autoreactive B cells are hypothesized to 
present beta cell antigens to CD4+ T cells (15).   
The presentation of islet antigen to CD4+ T cells elicits cytokine responses.  The balance 
between CD4+ T cell subsets has been suggested to be important for maintaining equilibrium 
between tolerance and autoimmunity.  A primarily IFN-γ, Th1 proinflammatory response is 
pathogenic in T1D, while polarizing with IL-4 and IL-10 to a Th2 phenotype was protective (80-
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82).  Also, TGF-β expression was found to skew APC and T cells, promoting a Th2 phenotype 
and protecting against T1D (83).  IL-10 was initially described as a regulatory cytokine, 
inhibiting IFN-γ (84, 85) and TNF-α production and activity (86), as well as antigen presentation 
(87) and monocyte cytokine production (88).  IL-10 inhibits macrophage function by decreasing 
cytokine synthesis and nitric oxide (NO) production (85).  Additionally, IL-10 exposure greatly 
affected the ability of macrophages to induce a Th1 response, suggesting IL-10 inhibition of 
macrophage APC function was indirectly suppressing Th1 function (85, 89).   
Natural Killer (NK) T cells are thought to provide a regulatory role and modify T helper 
responses.  NOD mice are shown to have a defect in NK T cells (90); transfer of NK T cells from 
(NOD x BALB)F1 donors can prevent T1D (91).  Defects in NK T cell numbers are correlated 
with decreased IL-4 production.  NOD mice compared to B6-H2g7 mice show reduced IL-4 
synthesis after anti-CD3 stimulation (91, 92), suggesting that NK T cells contribute to cytokine 
responses.  IL-4 expression protected NOD yet enhanced T cell autoreactivity in BDC2.5-NOD 
mice (93).  Treatment with recombinant IL-10 prevented disease when given systemically but 
was not protective when expressed in islets (94).  These discrepancies may be due to redundancy 
and compensatory roles of these cytokines, as well as tissue- and antigen-specific influences on 
T cell function.  Therapies to modulate T cell function, either by modifying activation or 
inducing regulation, have so far failed to translate to human trials (reviewed in (95)).  Difficulties 
in translating therapies from mouse to man, including evaluation of biomarkers, dosage, and 
timeframe of administration, still need to be overcome.  An important strategy for bridging the 
gap between mouse and human disease is the use of genetic tools to identify pathways and 
mutations that influence immune regulation, peripheral tolerance, and disease susceptibility. 
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B cells are important contributors to T1D development, producting islet-specific 
autoantibodies (96) and serving as potent APC.  Genetic ablation of immunoglobulin in NOD-
Igμnull protects mice from T1D (97-99).  However, while autoantibodies can induce beta cell 
damage in vitro, antibody administration fails to induce T1D in NOD-Igμnull mice (100).  B cells, 
expressing Class II MHC, are important APC, presenting antigen to CD4+ T cells.  The 
importance of this interaction is highlighted in NOD-Igμnull mice: CD4+ T cell reactivity to islet 
antigen is diminished when B cells are absent (100, 101).  Specific knockout of MHC II from B 
cells alone also provides significant protection from T1D onset, further demonstrating an 
essential role for B cells as APC, initiating the aberrant T lymphocyte responses that mediate 
beta cell killing (102). 
Selection mechanisms serve to delete or anergize B cells that recognize self-peptide; 
however, defects in selection may allow for the persistence of autoreactive B lymphocytes in the 
periphery.  Genetic linkages have associated B cell defects with T1D susceptibility in the NOD 
mouse model.  B cells from NOD mice are found to be hyperactive and resistant to activation-
induced cell death (103).  The Chromosome (Chr.) 4 linkage Idd9/11 locus is associated with the 
decreased tolerance of NOD B cells (104).  Identifying genetic control and, subsequently, 
pathways associated with B cell anergy may outline therapeutic targets for down-regulating 
autoimmune activation. 
While T cells are implicated as the final effectors mediating beta cell destruction, antigen 
presentation is required for lymphocyte activation, and defects in APC function and tolerance 
induction are associated with diabetes susceptibility.  Therefore, targeting APC function to 
promote tolerance and enhance regulation is a potential approach for T1D therapy.  In fact, as 
mentioned above, clinical trials focusing on DC therapy are currently underway.  B cells also 
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represent an essential pathogenic arm in autoimmunity.  Targeting B cell depletion through the 
use of anti-CD20 rituximab antibodies is also in early trials.  A potential drawback to rituximab 
therapy is the inability of the antibody to deplete marginal zone (MZ) B cells.  In NOD mice 
there is an expansion of MZ B cells around the time of T1D onset and an accumulation of MZ-
like B cells in the pancreatic lymph node (105), suggesting a pathogenic role in T1D.  
Additionally, MZ B cells are capable of presenting islet autoantigen to T cells (105), suggesting 
they serve as important APC.  Defining signaling differences associated with the Idd9/11 linkage 
may provide insight into the role of B cell anergy in T1D susceptibility/resistance.  Targeting 
APC function of MZ B cells may provide the additional immune regulation required to delay or 
prevent the onset of T1D.  Therefore, evaluating genes associated with risk in the NOD may also 
delineate the pathways associated with modified B cell anergy, T cell function, and T1D 
susceptibility. 
1.1.5 Genetics of T1D 
Type 1 diabetes is a polygenic disease, with over 50 genetic linkages associated with 
susceptibility or resistance.  However, the linkage to HLA Class II [termed Insulin-Dependent 
Diabetes Mellitus 1 (IDDM1)] is by far the dominant susceptibility locus (106).  DQB alleles 
with Ser, Ala, or Val at amino acid residue 57 are associated with T1D susceptibility, while those 
alleles containing an Asp residue are considered protective.  It is believed that the non-Asp- 
containing alleles cause a local rearrangement within the peptide-binding site, altering the 
peptide-binding specificity (107).  This mutation changes peptide alignment, altering T cell 
recognition and thymic selection (108).  Likewise, susceptibility has been linked to specific 
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HLA-A and HLA-B Class I alleles (109); however, little is known about the role of the disease-
associated variants in T1D. 
Additionally, several non-HLA linkages have been identified.  Genome-wide association 
studies (GWAS) have repeatedly associated INS [IDDM2], PTPN22 [IDDM5], and Cytotoxic T-
Lymphocyte Antigen 4 (CTLA4) [IDDM12] with T1D (106).  The INS locus contains a variable 
number of tandem repeats (VNTR) in the 5'-flanking region.  VNTR class I alleles with 26 to 63 
repeats are associated with recessive susceptibility, while the dominantly protective class III 
alleles have significantly more repeats.  The allelic effects on insulin gene transcription can be 
measured both in vitro and in vivo.  Class III alleles are proposed to induce higher thymic insulin 
expression and enhanced deletion of insulin reactive T cells (110).   
In the late 1980s, the first genome-wide screens of the NOD mouse strain were executed 
with the goal of identifying disease susceptibility/resistance loci or Idd (insulin dependent 
diabetes) (17, 111).  Over 30 linkages have been mapped in the mouse; however, only a few of 
the genes responsible have been identified.  Similar to the human condition, the most significant 
associations are with the MHC alleles (17, 111-113).  The NOD MHC class II molecules, I-Ag7 
(H2-Aag7), as well as the absence of H2-Ea expression, are critical for T1D development (95, 
114).  The H2g7 MHC haplotype of the NOD allele shares homology with the human T1D 
susceptibility HLA-DQB1 locus.  DQB alleles with Ser, Ala, or Val at position 57 are associated 
with T1D susceptibility, and the NOD H2-Ag7 also contains a non-aspartic residue at position 57 
(115-117).  Congenic replacement of the NOD H2g7 MHC haplotype with an alternative MHC 
haplotype, including the H2b of C57BL/6 (B6), prevents insulitis and overt diabetes development 
in NOD congenic animals (114).  These data demonstrate that alleles encoded within H2g7 are 
critical for T1D.  However, the introduction of H2g7 on a B6 background does not induce T1D, 
 14 
demonstrating that MHC alone is not sufficient to cause disease (114).  Likewise, in human 
populations only a minority of individuals with risk-associated HLA alleles develop diabetes.  
Transgenic mice have also been instrumental in demonstrating the diabetogenic potential of 
human HLA genes (118).  NOD mice transgenically expressing human risk HLA alleles, such as 
HLA-DR3 or DQ8, develop T1D.  Susceptibility, however, was modulated with the co-
expression of HLA-DR4 or DQ6 protective alleles, correlating with human epidemiological data 
(119, 120) and confirming the effect of HLA alleles on T1D susceptibility.   
Additionally, NOD mice expressing HLA-A*0201 and a deletion of the murine MHC 
class I genes (NOD.HHD) have an accelerated form of T1D (121, 122).  Class I alleles are 
associated with T1D in the mouse (123).  A polymorphism found in the alloxan resistant (ALR) 
strain and the diabetes-resistant cataract Shionogi (CTS) strain creates a unique allele H2-Ddx.  
Introducing this allele to the NOD background significantly reduces T1D (124).  Likewise, 
introduction of the MHC class I allele H-2Kwm7 to the NOD background confers some protection 
(123).  Analysis of the H-2Kwm7 MHC molecule defined a single peptide specificity (125).  This 
suggests that protection is afforded by the presentation of non-diabetogenic antigens rather than 
beta cell-specific antigen, due to higher affinity for a particular MHC allele.  Other associated 
genes have been mapped in the NOD and associated with T1D susceptibility and resistance.  A 
linkage on Chr. 1 mapped to the gene Βeta 2 microglobulin (B2m), an important component of 
the HLA/MHC.  Allele-associated risk was confirmed using transgenic rescue, demonstrating 
that the NOD allele provides dominant susceptibility (126).   
Other polymorphisms have been associated with T1D in human patients and animal 
models, including mutations in Nramp1.  While the polymorphism in the mouse is not identical 
to that in the human, the resulting sequence variations in both reduce expression and function of 
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the enzyme.  Using NOD models, including a novel RNA interference transgenic NOD for 
Nramp1, it was demonstrated that knockdown of Nramp1 was protective from T1D (127) and 
that the role of this enzyme was to alter processing and presentation of pancreatic islet antigens 
(128).  Another important mutation associated with risk in human and mouse is a single 
nucleotide polymorphism in mt-ND2 and mt-Nd2, respectively.  In both the human and mouse 
there is a C to A nucleotide substitution, resulting in a leucine to methionine amino acid 
substitution (129, 130), a mutation differentiating the NOD and ALR mouse strains.  The 
protective allele present in the ALR mitochondrial genome suppresses mitochondrial ROS 
production (131, 132).  This reduction in mitochondrial ROS has been highly correlated with 
enhanced protection against beta cell apoptosis (133, 134), highlighting an important role for 
ROS regulation in T1D resistance. 
1.2 REACTIVE OXYGEN SPECIES 
Free radicals, including reactive oxygen species (ROS), contain a reactive unpaired 
electron.  ROS, like superoxide and hydrogen peroxide, are continuously generated in the cell 
through various mechanisms.  Imbalances in free radical production and dissipation can 
contribute to oxidative stress.  Oxidative stress can alter or damage DNA, lipids, and proteins, 
contributing to disruption of cellular function and cell death (135-137).  In situations where 
excessive free radical production is warranted, such as at the site of inflammation, these 
molecules are important for anti-microbial responses but have been implicated in tissue injury.  
However, persistent elevation in ROS production and insufficient dissipation have been 
implicated in inflammation and pathogenesis of chronic conditions, including rheumatoid 
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arthritis, autoimmunity, ischemia, myocardial infarction, and other age-related diseases (138).  
While the toxic effects of free radicals are well recognized, ROS are also likely participants in 
basic cellular functions.  Transcription factors are regulated by redox status, demonstrating a role 
for free radicals in regulating gene expression (139).  Therefore, proper regulation of immune 
responses and free radical production is critical for sufficient pathogen clearance, as well as 
avoidance of chronic inflammatory conditions. 
1.2.1 NADPH oxidase 
There are several sources of intracellular ROS production, with major contributions 
provided by cell respiration in the mitochrondria and Nicotinamide Adenine Dinucleotide 
Phosphate (NADPH) oxidase complexes (NOX).  Professional phagocytes, including neutrophils 
and macrophages, are important contributors to innate immunity and early host responses to 
infection.  The primary anti-microbial defenses utilized by neutrophils are phagocytosis and the 
production of free radicals.  Neutrophils produce ROS, specifically superoxide, via the 
enzymatic NOX complex, which is critical for phagocytosis and pathogen clearance (140, 141).  
NOX is an enzyme complex of six subunits.  There are two trans-membrane proteins, p22phox 
and gp91phox, which constitute the catalytic component cytochrome b558 (142, 143).  The other 
subunits p47phox, p67phox, p40phox and a GTPase, such as Rac, are localized in the cytoplasm 
during the inactivated state (142).  Physical separation of these subunits provides important 
spatial regulation of activity and free radical production by preventing any basal free radical 
production by NOX (143, 144).   
PMN exist in three different states, resting, primed, and activated, that are determined by 
the presence of external stimuli (145-147).  Resting cells are quiescent, present in circulation, 
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with a round morphology.  Proinflammatory stimuli induce morphological changes and adhesion 
to the endothelium.  These primed PMN follow chemotactic gradients to the site of 
inflammation, where they become activated (145-149).  Rapid priming stimuli, including PAF, 
C5a, and lysophosphatidylcholine (LPC), induce effects within 3-5 minutes, whereas long-acting 
agents like lipopolysaccharide (LPS), IFN-γ and TNF-α can take hours.  In some cases, the 
binding of stimulus agents to G-protein-coupled receptors primes the oxidase.  The recognition 
of activating agents, including formyl-Met-Leu-Phe (fMLP), OpZ, and phorbol 12-myristate 13-
acetate (PMA), induces the assembly of all NOX subunits, fully activating PMN and superoxide 
production (150-152).  Agonist binding to the receptor starts signaling cascades in which the 
activation of phospholipases is mediated by a G protein and PtdInsP2 is broken down into DAG 
and Insp3.  Insp3 binds intracellular calcium (Ca2+) stores.  The subsequent release of Ca2+, 
along with DAG, activates Protein Kinase C (PKC).   
Activated PKC catalyses the phosphorylation of the NOX cytosolic subunits, including 
p47phox, p67phox and p40phox, exposing unique binding domains.  p47phox contains four 
domains: the N-terminus, internal SH3 domain, auto-inhibitory domain, and proline-rich C-
terminus (153-158).  The N-terminus phox homology domain targets p47phox to the plasma 
membrane upon activation; however, during the resting state the SH3 domain binds the auto-
inhibitory domain (159-162).  This interaction obscures the translocation domain, providing 
localization in the cytoplasm when not activated.  Phosphorylation of p47phox removes the 
inhibition.  This initiates translocation to the plasma or vesicle membrane and binding to the 
transmembrane subunit p22phox.  This interaction facilitates binding of p40phox and p67phox to 
cytochrome b558 and the formation of the active complex (163, 164).  The transfer of electrons 
from NADPH across the membrane to molecular oxygen results in the reduction of oxygen into 
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superoxide (143, 145).  The produced superoxide can be dismutated into hydrogen peroxide by 
enzymes of the superoxide dismutase (SOD) family.  Degranulation releases myeloperoxidases, 
which catalyze the reaction of hydrogen peroxide with chloride anions to generate hypochlorous 
acid.  This can be followed by N-chlorination of nitrogen-containing compounds, producing 
chloramines.  All of these products contribute to free radical-mediated antimicrobial killing (141, 
144), which could result in oxidative stress in situations where the production is excessive. 
The production of superoxide and subsequent free radical products is critical for pathogen 
clearance.  The necessity of respiratory burst elicited by neutrophils and macrophages is 
highlighted by the rare condition Chronic Granulomatous Disease (CGD).  Patients with CGD 
present with chronic, recurring bacterial and fungal infections as well as formation of 
granulomas in multiple tissues (165).  An inherited disorder, CGD was linked to defective 
neutrophil and macrophage respiratory burst caused by mutations in genes encoding NOX 
subunits, including gp91phox, p22phox, p67phox, and p47phox.  Mutations in gp91phox, which 
are X-linked (166, 167), are found in roughly two-thirds of CGD patients, with various types of 
mutations being detected (165, 168).  Missense, nonsense and splicing mutants have been 
described, contributing to a variety of structural and/or functional changes in gp91phox.  
Mutations in the phenylalanine residues result in the absence of cytochrome b558 (166).  
Carriers of gp91phox mutations also exhibit decreased activity and defective microbial defenses 
(169).   Mutations in the p47phox subunit are found in about 25% of CGD cases, with the 
predominant mutation resulting in an early stop codon, disrupting binding and activation (168).  
Retroviral vectors have been used in the gp91phox mutant mouse model of CGD to restore NOX 
function, eradicate infections, and eliminate the granulomas (170).  Clearly, NOX superoxide 
production is important for proper acute responses and pathogen clearance. 
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1.2.2 ROS and inflammation 
NOX function is needed to control infection, however too much or dysregulated 
production can increase risk of tissue damage.  Increased free radical production, insufficient 
dissipation, and uncontrolled ROS production have all been implicated in inflammation and 
pathogenesis of chronic conditions and autoimmunity. 
Study of genes linked to arthritis susceptibility in rats identified Ncf1 (Neutrophil 
cytosolic factor 1), encoding the p47phox subunit of NOX, which was surprisingly associated 
with defective neutrophil respiratory burst (171).  Contrary to the hypothesis that ROS is 
proinflammatory in arthritis, Ncf1 mutant animals lacking superoxide production showed 
enhanced arthritis and encephalomyelitis, whereas activating NOX ameliorated arthritis (172).  
These data contradicted earlier reports showing Ncf1 knockout mice to be resistant to myelin 
oligodendrocytic glycoprotein (MOG) 35-55 peptide-induced experimental allergic 
encephalomyelitis (EAE) (173).  Also, Ncf1 mouse mutants with deficient superoxide production 
demonstrate increased susceptibility to and severity of collagen-induced arthritis (CIA) and EAE 
(172).  It is important to note that the EAE-inducing agents in the rat and mouse studies differ by 
the use of native myelin proteins and myelin protein-derived peptides, respectively.  This 
dramatic difference in susceptibility may highlight a potential role for ROS in antigen processing 
and presentation.  Oloffsson, Holmdahl et. al. show that adoptive transfer of arthritogenic, 
mitogen-activated spleen cells only transferred disease when the donor was NOX-intact, 
suggesting that NOX function is important for priming pathogenic CD4+ T cell responses (171).  
The authors suggest that ROS may be important for T cell and macrophage apoptosis or 
inhibitory signals, which are lost in the absence of NOX function, leading to the increased 
inflammatory response. 
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Free radical production is proposed to be an important contributor to beta cell death in 
various capacities (Figure 1).  As beta cells have low free radical defenses, they are sensitive to 
fluctuations in redox balance (174, 175).  NOX free radical production by cells of the innate 
immune system, including neutrophils and macrophages, can have direct cytotoxic effects on the 
beta cell.  During antigen presentation, free radicals are hypothesized to be important 
intracellular and intercellular signaling molecules (140, 176, 177).  T cell ROS production is 
important during signaling and directing lineage development and cytokine synthesis.  Cytokine 
and chemokine signaling further recruits and activates immune cells, amplifying inflammation 
(34, 36).  Cytokines can then increase free radical production in the beta cell, contributing to beta 
cell death.  Specifically, cytokines, including IL-1β and IFN-γ, induce elevated iNOS expression 
and NO production, contributing to beta cell apoptosis (73, 178).  Recent work suggests that 
NOX complex subunits are expressed in beta cells and produce superoxide upon stimulation; 
however, a role during the inflammatory process and beta cell killing is not yet determined. 
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Figure 1.  Free Radical Production is an important contributor to beta cell death.  Cells of the innate 
immune system, including neutrophils and macrophages, produce superoxide via NOX and these free radicals can 
have direct cytotoxic affects on the beta cell.  Free radicals produced during antigen presentation influence cytokine 
production and can cross cell membranes, participating during intercellular signaling.  Intracellular T cell ROS is 
proposed to contribute to directing lineage development and cytokine production.  Cytokine activity upregulates free 
radical production in the beta cell, contributing to beta cell death. 
1.2.3 ROS as signaling molecules 
The literature has recently been shifting focus from implicating ROS as damaging 
byproducts of cellular function to describing an essential role for free radicals as secondary 
messengers during signal transduction and signal amplification.  ROS signaling is now 
implicated in the function of immune cells, including T lymphocytes (176).  Redox status 
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systems, including NADPH, thioredoxin, and glutathione, are implicated in contributing to 
intercellular and intracellular T cell signaling (176).  While mitochondria are considered the 
major source of free radicals (179), reports suggest that T cells express NOX-like molecules 
(180-182).  Though the finding is controversial, T cell production of superoxide by a NOX 
enzyme is also reported.  Previous work with gp91phox knockout mice has not demonstrated a 
clear role for NOX ROS production by T cells (181, 183).  The introduction of a dominant 
negative Rac1 eliminated T cell ROS production (182); however, gp91phox deficiency did not 
fully ablate free radical production (181).  In the T1D-prone NOD mice, polyclonal activation of 
T cells via anti-CD3 crosslinking stimulation elicits free radical production.  The introduction of 
a p47phox mutation in NOD congenic mice ablates ROS production from CD4+ T lymphocytes 
((184) & Chapter 4).  The introduction of this mutation has profound effects on macrophage and 
T cell function, as well as diabetes susceptibility with NOX-deficient immune cells ((184) & 
Chapter 4). 
Modulation of ROS has been associated with regulation of Ras/Raf, Protein Kinase C and 
MAP kinase cascade pathways (185).  It has previously been shown that depletion of APC 
intracellular glutathione shifts T helper polarization (186), demonstrating a role for ROS during 
antigen presentation and cytokine production.  Hydrogen peroxide, a dismutation product of 
superoxide, is produced during oxidative burst and is proposed to play a role in lymphocyte 
antigen receptor activation (187-190).  With similarities to calcium, hydrogen peroxide can 
easily diffuse inside a cell and between cells because it is electrically neutral (189, 191).  
Peroxides facilitate the oxidation of proteins, specifically cysteine residues (192, 193).  
Important targets of peroxide oxidation are transcription factors like p53, Jun, and NF-κB 
subunit p50, and this regulates transcriptional activity (139, 194). 
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Redox status and ROS production are associated with immune activation and the 
recruitment of lymphocytes.  NOX function has been linked to altered T cell migration.  The 
blockade of ROS production inhibits AP-1 activation and IL-8 synthesis (195), which are 
important contributors to chemotactic signals (19).  Additionally, the upregulation of SOD and 
catalase in endothelial cells reduced monocyte chemoattractant protein-1 (MCP-1) induction 
(196).  ROS production is proposed to be involved in the signaling between macrophages and 
lymphocytes (32, 197).  As close contact is achieved at the immunological synapse during 
antigen presentation, free radicals are hypothesized to leave the oxidizing environment in the 
macrophage, diffusing to the lymphocyte (32, 198).  Increases in hydrogen peroxide shift the 
antigen-specific dose response during B cell activation, suggesting that low-affinity BCR can be 
activated when redox status is shifted (189, 199).  Macrophage-produced ROS is also suggested 
to pass to T lymphocytes.  Proinflammatory third signals require ROS production to elicit APC 
cytokine production and lymphocyte effector function (200-202).  This is achieved through 
regulation of transduction pathways and transcription factors that are affected by redox status, 
including NF-κB, STAT, and AP-1 (185, 203-205).  ROS scavenging was found to suppress 
TCR-induced transcription of NF-κB and AP-1 (176, 206).  Upregulation of these genes is 
associated with transient ROS fluxes.  These responses are dependent on immune-derived 
signals.  Blocking these innate-derived signals with catalytic antioxidants resulted in antigen-
specific hyporesponsiveness, decreasing T cell proliferation and cytokine synthesis (202).  These 
alterations to redox balance, using catalytic antioxidants or metalloporphyrin-based superoxide 
dismutase mimics, also had profound effects on diabetes development and transfer, associated 
with modified lymphocyte reactivity (202, 207-210). 
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Intracellular T cell ROS production is also critical during signal transduction and lineage 
commitment.  In T cells, the engagement of CD28 stimulates rapid production of ROS that is 
required for NF-B activation and IL-2 expression (211), processes important for cell function, 
survival and proliferation.  Additionally, reports suggest that activation-induced cell death 
(AICD) of T cells requires free radicals, as antioxidants inhibit AICD in T cell lines and primary 
cells after exposure to various stimuli (212-216).  Cell death of naïve thymic T cells was 
abolished during hypoxic conditions (217).  Furthermore, reductions in oxygen concentrations 
skewed CTL development and cytokine production (218).  These data suggest that oxygen levels 
and oxygen-derived radicals are important for T cell survival and differentiation. 
1.2.4 Antioxidant therapy for T1D protection 
As oxidative stress is associated with exacerbated inflammation and beta cell death, free 
radical scavengers and antioxidants have been proposed as potential therapeutics for diabetes.  It 
has been previously reported that antioxidants were able to delay and prevent the transfer of T1D 
by diabetogenic T cells (207, 210), suggesting that scavenging ROS interfered with 
proinflammatory autoimmune initiation.  Several reports showed that the modification of 
antioxidant activity was able to reduce or prevent IL-1β-induced beta cell damage (219, 220).  
Beta cell over-expression of SOD1 reduced damage induced by the diabetogenic drugs alloxan 
and streptozotocin (221).  Glutathione, SOD1, and thioredoxin (TRX) have been shown to block 
pro-apoptotic pathways involving apoptosis signal-regulating kinase, AP-1 and NF-κB (222, 
223).  Recombinant TRX also protected islets from TNF- and Fas-induced apoptosis (224); 
transgenic over-expression of TRX, specifically in the beta cells of NOD mice, significantly 
reduced incidence of T1D (225).  Additionally, administration of the metalloporphyrin-based 
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SOD mimetic was able to protect mice from T1D induction by diabetogenic T cell clones (210).  
These data demonstrate a role for antioxidants in regulating apoptosis and immune-mediated beta 
cell death.  Likewise, modifying redox balance attenuates immune cell activity; as systemic 
administration reduces inflammation, antioxidant therapy may also serve to skew pathogenic 
immune responses.  Therefore, therapeutic manipulation of ROS in beta cells or cells of the 
immune system could have dramatic effects on T1D onset. 
1.2.5 The ALR Mouse 
The Alloxan Resistant (ALR) mouse strain, selected for resistance to alloxan-induced 
diabetes, is very useful for the study of redox balance, free radical dissipation, and resistance to 
autoimmunity.  Alloxan is selectively taken up by beta cells through GLUT2.  Once inside beta 
cells, alloxan decomposes and generates free radicals, inducing cell death.  The ALR strain was 
outbred from the Jc1:ICR swiss progenitors from which the NOD strain was also derived.  The 
NOD and ALR are closely related, with over 85% genetic identity between the strains, including 
almost all Idd loci (133).  Analyses of IL-2, β2m, (112) and MHC class II alleles (226) revealed 
identical sequences comparing NOD and ALR.  Though closely related to the NOD, the ALR 
mouse strain resists spontaneous and induced forms of diabetes.  ALR islets also exhibit 
exquisite resistance to cytotoxic T cells and proinflammatory cytokines.  Not surprisingly, the 
ALR demonstrates heightened free radical defenses with elevated activity of superoxide 
dismutase (SOD), glutathione peroxidase, and glutathione reductase, which also extends to the 
pancreatic islets (227-229).  Additionally, cellular sources of free radical production, including 
mitochondria respiration, iNOS activity, and cytosolic NOX function, are impaired in the ALR, 
producing significantly lower amounts of ROS (17, 128, 131, 133, 228, 230).  As the ALR is 
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distinguished by heightened antioxidant defenses and decreased free radical production, these 
characteristics are proposed to be critical in ALR-derived protection.  Investigating the genetics 
of ALR compared to the T1D-prone NOD provides a unique analysis to describe protective 
mechanisms involved in the activation of autoreactive effectors and beta cell killing. 
Genetic analyses identified ALR-derived protective loci on Chr. 3, 8 and 17, as well as a 
single nucleotide polymorphism in the mitochondrial genome.  The peak linkage on Chr. 17 
mapped to the MHC.  It is important to note that ALR and NOD differ at the distal end of the 
MHC complex, encoding H2-Ddx and H2-Db, respectively (112).  The mitochondrial linkage is 
associated with the single nucleotide polymorphism in mt-Nd2, representing the only genetic 
difference in the mitochondrial genome between ALR and NOD.  As previously discussed, the 
ALR-derived allele is associated with reduced mitochondrial ROS production, which has been 
highly correlated with enhanced protection against beta cell apoptosis (133).  The linkage 
mapping to Chr. 8, termed Idd22, has not been mapped in other genome-wide association studies 
using other outcross partners, suggesting that the protective loci may be unique to the ALR 
strain.  Idd22 has been associated with ALR-derived resistance to both spontaneous T1D and 
alloxan-induced ROS-mediated diabetes (112, 133).  
The locus on Chr. 3 overlapped with an independently mapped locus, Suppressor of 
Superoxide Production (Susp), that was associated with both reduced superoxide production by 
NOX and heightened SOD1 activity (230).  The mapping of an Idd to Chr. 3 is not surprising, as 
multiple linkages have been mapped to this chromosome via backcrosses of NOD with B10, B6, 
or NON mouse strains.  These linkages have been designated as Idd3, 10, 17, 18.  However, the 
IL-2 allele, the candidate for Idd3, is identical in ALR and NOD (112), and the diagnostic 
markers for Idd10, 17, and 18 are non-polymorphic comparing the strains, suggesting that the 
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ALR-derived locus on Chr. 3 may be novel rather than resulting from alleles at Idd3, 10, 17, or 
18.  These data suggest that Susp phenotypic contributions may be involved in ALR-derived 
T1D resistance. 
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2.0  ALR-DERIVED CHROMOSOME 3 SUPPRESSOR OF SUPEROXIDE PRODUCTION 
DOMINANTLY PREVENTS TYPE 1 DIABETES AND INSULITIS  
2.1 ABSTRACT 
Free radicals are involved during various stages of autoreactivity and beta cell 
destruction.  In addition to contributing to beta cell killing, reactive oxygen species (ROS) are 
important signaling molecules during the initiation of proinflammatory effectors.  The Alloxan 
Resistant (ALR) mouse is uniquely resilient to oxidative stress, exhibiting elevated antioxidant 
defenses and reduced production of ROS.  We have previously associated increased superoxide 
dismutase 1 (SOD1) activity with suppressed superoxide production (Susp) by neutrophils and 
macrophages.  The ALR Susp locus overlapped with a previously identified ALR-derived T1D 
protective locus on Chromosome (Chr) 3, suggesting elevated SOD1 and reduced NADPH 
oxidase (NOX) function contribute to diabetes resistance.  The role of SOD1 regulation and free 
radical scavenging were studied to determine the impact of the ALR-derived Chr. 3 loci on beta 
cell survival and diabetogenicity of T lymphocyte effectors. 
To determine the role of Susp in T1D-prone model, the ALR-derived Susp locus on Chr. 
3 was congenically introduced to the NOD background (NOD-Susp).  NOD-Susp mice exhibited 
ALR-like activities of both SOD1 and NOX confirming the previous mapping of Susp to Chr. 3.  
Additionally, elevated SOD1 activity was associated with increased stability of SOD1 dimer in 
 29 
NOD-Susp mice.  The association of SOD1 with NOX function was confirmed by assaying 
respiratory burst in the presence of a SOD1 inhibitor, potassium cyanide.  Inhibition of SOD1 
restored superoxide production by PMA-stimulated bone marrow cells isolated from ALR and 
NOD-Susp mice. 
Congenic introduction of ALR Chr. 3 genome to an NOD background dominantly 
protected mice from diabetes onset and insulitis development.  Cultured islets from the NOD-
Susp congenic mice were assessed for viability after proinflammatory cytokine treatment and 
mice were challenged with adoptive transfer of splenocytes from NOD-AI4 transgenic mice.  
However, NOD-Susp islets did not exhibit full protection from cytokine-mediated death and 
mice were hyperglycemic after adoptive transfer of AI4 splenocytes, demonstrating 
susceptibility to inflammatory mediators.  The diabetogenic potential of T cells purified from 
NOD and NOD-Susp donors was assessed via adoptive transfer to susceptible NOD-Scid 
recipients.  Purified T cells from NOD-Susp donors failed to induce diabetes in NOD-Scid mice.  
Therefore, ALR Chr. 3 is providing significant modification to immune cell reactivity, reducing 
beta cell-specific effector function by T cells from NOD-Susp donors. 
These data demonstrate that ALR Chr. 3 contributions provide significant resistance to 
diabetes.  The protection provided is associated with the elevated SOD1 activity.  However, this 
increased antioxidant scavenging did not provide enhanced beta cell survival.  Rather, the 
immune system from NOD-Susp mice lost diabetogenic potential.  We have previously shown 
that NOX function is important for immune cell diabetogenic reactivity.  Taken together, these 
data suggest that antioxidant regulation of oxidative stress is a major modifier of immune 
effector function and diabetes development. 
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2.2 INTRODUCTION  
Type 1 Diabetes (T1D) results from the autoimmune destruction of the insulin secreting 
pancreatic beta cells.  Immune-mediated attack involves various mechanisms that induce beta 
cell death, including Fas/FasL engagement, proinflammatory cytokine synthesis, and production 
of free radicals (reviewed in (231)).  Reactive oxygen species (ROS) production is involved 
during various stages of autoreactivity and beta cell destruction (Fig. 1).  ROS not only serve as 
cytotoxic mediators, but also as critical signaling molecules during activation of innate and 
adaptive immune responses (140, 177, 202, 207, 208).  However, the role of ROS production and 
antioxidant scavenging in the development of spontaneous T1D is ill-defined (133, 176). 
The Alloxan resistant (ALR) mouse strain was selected based on resistance to alloxan-
induced free radical-mediated diabetes.  The NOD and ALR are closely related with over 85% 
genetic identity between the strains (133).  Despite the high genetic similarity, the ALR is 
resistant to spontaneous diabetes and to adoptive transfer with diabetogenic T cells (232).  ALR 
islets also exhibit exquisite resistance to cytotoxic T cells and proinflammatory cytokines (229, 
232).  Not surprisingly, the ALR demonstrates heightened free radical defenses with elevated 
activity of superoxide dismutase (SOD), glutathione peroxidase, and glutathione reductase (228, 
229, 232).  Systemic and constitutive elevations of SOD1 activity were associated with increased 
stability of SOD1 dimer.  The ALR mouse represents a unique model to study the role of ROS 
scavenging as well as free radical production in the development of aberrant immune responses 
and T1D resistance (112, 133, 226, 233). 
Genetic analyses identified ALR-derived protective loci on Chr. 3, 8 and 17 (112, 226, 
230), as well as a single nucleotide polymorphism in the mitochondrial genome (129).  The locus 
on Chr. 3 overlaps with an independently mapped locus, Suppressor of Superoxide Production 
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(Susp), controlling reduced superoxide production by NADPH oxidase (NOX) (230).  This 
reduction in NOX function was associated with the systemic and constitutive elevation of SOD1 
activity (230).  These data suggest that Susp phenotypic contributions may be involved in ALR-
derived T1D resistance.  To study to role of Susp in T1D-prone model, NOD mice congenic for 
the Susp locus were developed.  Congenic mice inherited ALR-like phenotypes of elevated 
SOD1 and reduced NOX function.  Inhibition of SOD1 activity was able to restore superoxide 
production by PMA-stimulated ALR bone marrow cells, demonstrating that increased 
superoxide turnover was reducing the release of free radicals.   
Here we show that ALR Chr. 3 contributions dominantly protected mice from T1D onset 
and invasive insulitis.  Though completely protected from spontaneous T1D onset, NOD-Susp 
islets were not fully resistant to cytokine-induced death and congenic mice were equally 
susceptible as NOD cohorts to adoptive transfer with AI4 CD8+ T cells, demonstrating that beta 
cells did not exhibit the same resistance to proinflammatory mediators.  However, transfer of T 
cells from NOD-Susp donors failed to induce diabetes in susceptible NOD-Scid recipients, 
demonstrating a loss of diabetogenic potential.  These data suggest that elevated free radical 
scavenging at the immune cell level is most effective to reduce beta cell-directed autoimmunity. 
2.3 METHODS 
2.3.1 Animals 
The ALR-derived Susp locus was congenically introgressed into the NOD genome.  In 
order to generate congenic mouse model female NOD mice were mated with male ALR mice, 
 32 
and the subsequent F1 progeny were backcrossed to NOD.  Selection for ALR contributing 
genome on Chr. 3 and elimination of contaminating ALR alleles elsewhere in the genome was 
achieved through PCR amplification of six microsatellite primer pairs on Chr. 3 and an 
additional 94 informative microsatellite primers spanning all chromosomes at each generation 
from N2 to N7 as previously described (132).  Mice were backcrossed for a total of 10 
generations, followed by intercrossing to select NOD mice with ALR homozygous Susp locus.  
The congenic mice used throughout this report are NOD.ALR-(D3Mit221-D3Mit189) [NOD-
Susp] with a congenic segment of ALR genome spanning from D3Mit221 (7.89 Mbp) to 
D3Mit189 (100.78 Mbp). 
ALR/LtJ, NOD/ShiLtJ, NOD.B6-Ncf1m1J/m1J [NOD-Ncf1m1J], and NOD-Susp mice were 
bred and housed in the University of Florida facility under specific pathogen-free conditions.  
NOD.CB17-Prkdcscid/J [NOD-Scid], NOD.129S7 (B6)-Rag1tm1Mom/J [NOD-Rag1], NOD.Cg-
Rag1tm1MomTg (TcraAI4)1Dvs/DvsJ [NOD-AI4a] and NOD.Cg-Rag1tm1MomTg 
(TcrbAI4)1Dvs/DvsJ [NOD-AI4b] were purchased from The Jackson Laboratory (Bar Harbor, 
ME) and bred in our mouse facility.  F1 hybrid progeny from matings of NOD-AI4a with NOD-
AI4b [NOD-AI4a/b] developed diabetes between 3-5 weeks of age.  All mice were housed in 
specific pathogen-free facilities and approved by the Institution Animal Care and Use Committee 
of the University of Florida. 
2.3.2 Materials 
Riboflavin, TEMED, potassium cyanide (KCN), 5-(and-6)-chloromethyl-2’7’-
dichlorodihydrofluorescein diacetate (CM-H2DCFDA), and 4-alpha-phorbol-12-myristate-13-
acetate (PMA) were purchased from Sigma-Aldrich (St. Louis, MO).  Dihydrorhodamine 123 
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(DHR123) was purchased from Invitrogen (Carlsbad, CA) and Dithiotheitol (DTT) from Bio-
Rad (Hercules, CA).  Superoxide Dismutase activity assay kit was purchased from Cayman 
Chemical (Chantilly, Virginia).  All DNA oligonucleotides were obtained from Integrated DNA 
Technologies, Inc. (Coralville, Iowa). 
2.3.3 Gene expression analysis 
RNA was purified from liver using TRIzol Reagent [Life Technologies (Rockville, 
MD)].  cDNA was generated using the SuperScript First-Strand Synthesis System [Life 
Technologies].  The primer set used to measure the relative expression of Sod1, Sod1.F - GCA 
AGC GGT GAA CCA GTT GT and Sod1.R - CCA ACA TGC CTC TCT TCA TCC] was 
validated before use by sequencing of the amplified PCR product to determine specificity.  
Amplification with a primer set specific for 18S rRNA, 18S.F - CCG CAG CTA GGA ATA 
ATG GAA T and 18S.R – CGA ACC TCC GAC TTT CGT TCT, was utilized for normalization.  
The tests were run using 3 pools of liver cDNA per group and fluorescence detected by an ABI 
Prism 7700, using SYBR Green JumpStart Taq Ready Mix (Sigma) for detection as per 
manufacture’s protocol. Quantitative Real-Time PCR conditions were an initial 2 min 
denaturation step at 94°C, followed by 45 cycles of (94°C for 30 sec, 60°C for 30 sec, and 72°C 
for 60 sec), and then finally at 4°C hold. 
2.3.4 Sequencing of Sod1 
Total liver RNA was isolated and cDNA synthesized as above.  PCR was used to amplify 
the SOD1 coding sequence using primers specific for SOD1 [Sod1-Seq.F: CTC TCT GGT CCC 
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TCC GG: Sod1-Seq.R: GTC CTT AGC CCA GTC AAA GG].  PCR conditions were 2 min 
initial denaturation step at 94°C, followed by 45 cycles of (94°C for 30 sec, 60°C for 30 sec, and 
72°C for 60 sec), and then finally a 4°C hold.  Sequencing was performed on an ABI 3100 using 
big dye chemistry (ABI (Carlsbad, CA)).  Sequences were aligned and analyzed using the 
Sequencher software package. 
 
2.3.5 Western blotting 
Whole cell lysates were separated on a 4-20% gradient SDS-PAGE gel and transferred 
onto nitrocellulose membrane.  The membranes were incubated overnight at 4°C with polyclonal 
anti-SOD1 antibody (Santa Cruz or Millipore) and exposed to the appropriate secondary 
antibody conjugated to horseradish peroxidase (Jackson ImmunoResearch or Santa Cruz).  
Chemiluminescence was detected with SuperSignal Chemiluminescent Substrate (Thermo 
Scientific). 
2.3.6 Assessment of SOD1 activity 
Liver and bone marrow homogenates were prepared in 20 mM HEPES buffer (pH 7.2) 
with 1 mM EGTA, 210 mM mannitol and 70 mM sucrose.  Protein content was determined using 
Pierce BCA Protein Assay Kit (Thermo Scientific).  SOD1 was extracted using 
ethanol:chloroform (62.5/37.5 v/v).  After centrifugation at 3000 x g for 5 min, the aqueous layer 
containing SOD1 was collected.  SOD1 activity was measured with Cayman Chemical 
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Superoxide Dismutase Assay Kit following manufacturer’s protocol.  Pretreatment of lysates 
with 2 mM KCN confirmed full inhibition of SOD1 activity. 
2.3.7 Evaluation of SOD1 stability 
Red blood cell lysates were prepared in 0.5 M potassium phosphate buffer (pH 7.8).  
Samples were treated with Dithiothreitol (DTT) for 2 hours at 37°C.  Thermal stability was 
assessed by incubation of lysates at 75°C, 85°C, or 95°C for 5 min.  DTT-treated, heated, and 
control lysates were then separated on a 12% non-denaturing acrylamide gel with a 5% stacker.  
The gel was then saturated in 2.45 mM Nitroblue Tetrazolium (NBT) for 20 min at room 
temperature followed by saturation with 28 μM Riboflavin with 25 mM TEMED in 36 mM 
potassium phosphate (pH 7.8) for 15 min at room temperature.  Gels were illuminated under 
fluorescent light until full contrast was obtained (234). 
2.3.8 Cytochrome c measurement of oxidative burst 
Bone marrow was collected from age-matched female mice and red blood cells were 
removed on a Histopaque-1119 gradient as previously described (230).  1x105 cells were 
pretreated with 2 mM KCN or HBSS for 15 min at room temperature.  Cells were then 
transferred to HBSS containing 145 μM cytochrome C and were stimulated with PMA (98 nM) 
at 37°C.  Reduction of cytochrome C was measured at 550 nm at 1 min intervals for 45 min.  
The maximum rate of reduction was calculated by linear regression analysis.  Purified bovine 
erythrocyte SOD1 (Cayman Chemical) (0.5 U/mL) was used to confirm specificity of superoxide 
production. 
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2.3.9 Measurement of oxygen consumption 
Bone marrow was collected from age-matched female mice and red blood cells were 
removed on a Histopaque-1119 gradient as previously described (230).  The Oxygraph-2K 
(Oroboros Instruments Innsbruck, Austria) was calibrated for basal oxygen levels with HBSS 
and after the addition of sodium hydrosulfite, following manufacturer’s instructions.  A total of 
2x107 cells were pretreated with 2 mM KCN or HBSS for 15 min at room temperature.  Cells 
were resuspended in 2 mL HBSS and loaded into the chamber of the Oxygraph-2K at 37°C.  
Samples were stimulated with 1 µM PMA and oxygen concentration and rate of consumption 
were monitored for 30 min. 
2.3.10 Spontaneous incidence 
At 8 weeks of age, NOD-Susp female and male mice were enrolled and monitored for 
diabetes onset via weekly urinalysis testing using Diastix [Bayer (Elkhart, IN)] and compared 
with NOD-Susp(F1), NOD-Susp(NOD) littermate controls, and NOD cohorts.  Mice positive for 
glucosuria were monitored daily thereafter for hyperglycemia using One Touch Ultra 2 meters 
[Life Scan, Inc (Milpitas, CA)].  Any mouse with measured blood glucose levels on consecutive 
days >250 mg/dL were diagnosed with type 1 diabetes.  To examine islet inflammation of non-
diabetic females from each genotype at 30 weeks of age pancreata were fixed in 10% neutral 
buffered formalin, embedded in paraffin, stained with aldehyde fuchsin to identify granulated 
beta cells, and counter-stained with hematoxylin and eosin.  Islets were scored over a range 
between 0 (no lesions) and 4.0 (end-stage insulitis) and a mean insulitis score calculated.   
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2.3.11 Islet isolation and culture with cytokines 
Pancreatic islets from age-matched female NOD-Rag1 and NOD-Susp mice were isolated 
(235) and cultured with IFN-γ, IL-1β, and TNF-α as previously described (232).  Islet NO 
production was measured and cell viability was assessed via MTT assay as previously reported 
(228).  
2.3.12 Transfer of AI4 splenocytes 
At 3-4 weeks of age, NOD-AI4a/b donors were sacrificed and splenocytes were 
harvested.  After the red blood cells were lysed with Gey’s solution live cells were counted and 
diluted to a concentration of 108 cells per mL.  A total of 2 x 107 cells in sterile PBS were 
injected via the tail vein into sub-lethally irradiated eight week old NOD and NOD-Susp females 
[dose of 7.5 Gy delivered using X-RAD 320 (Precision X-ray, North Branford, CT)] as 
previously described.  Mice were monitored every other day for the onset of diabetes as 
described above. 
2.3.13 Flow cytometric analysis of oxidative burst 
Neutrophil and macrophage superoxide production were also assayed using a FACS 
assay, as previously described (230).  Briefly, bone marrow was isolated and purified using a 
Histopaque-1119 gradient.  Cells were labeled with PerCpCy5.5-labeled anti-Ly6g (Gr1) and 
APC-labeled anti-CD11b and then loaded with Dihydrorhodamine 123 (DHR 123) for 5 minutes 
at 37°C.  Cells were subjected to flow cytometry prior to stimulation, and then at 5 minute 
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intervals after PMA [98 nM] stimulation.  The ROS driven conversion of DHR 123 to rhodamine 
was measured using a BD Fortessa.  Data were collected and analyzed with FACSDiva software 
(BD Biosciences). 
2.3.14 Determination of anti-CD3 induced ROS generation in purified CD4+ T cells 
ROS generation was measured with the oxidation-sensitive dyes CM-H2DCFDA as 
described previously (181) with the following modifications (Tse and Thayer, In Press).  CD4+ T 
cells were purified with a CD4+ T cell isolation kit (Miltenyi Biotec) per the manufacture's 
guidelines.  Purified 107 CD4+ T cells were stained with CM-H2DCFDA (Sigma) 2µM at 37°C 
for 30min, washed and then stained with hamster anti-mouse CD3 Ab (BD Pharmingen) at 
10µg/ml for 25 min at 4°C.  ROS generation was induced in 106 CD4+ T cells by cross-linking 
the anti-CD3 antibodies with 5 µg/mL rabbit anti-hamster IgG (BD Pharmingen) at 37°C.  
Fluorescence was detected with a BD Fortessa at 0, 30, and 60 min after stimulation.  ROS 
generation was determined by the increase in CM-H2DCFDA fluorescence upon anti-CD3 
stimulation over unstimulated control.  The increase in dye oxidation was calculated as the 
percentage increase in mean fluorescence intensity (MFI) of anti-CD3 stimulated cells over 
unstimulated cells for each time point using the following equation: 
([MFI(stim)-MFI(unstim)] / MFI(unstim)) x 100. 
2.3.15 Adoptive transfer of purified T cells from NOD and NOD-Susp 
Eight week old, female NOD and NOD-Susp donors were used for adoptive transfer 
experiments.  All donors were diabetes free at the time of sacrifice.  Splenocytes were harvested 
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and red blood cells were lysed using Gey’s solution.  CD4+ and CD8+ T cells were purified by 
negative selection with magnetic beads according to the manufacturer’s protocol using a CD4+ T 
cell isolation kit or a CD8+ T cell isolation kit (Miltenyi Biotec), respectively.  Purity, over 96%, 
was confirmed by flow cytometric analysis.  CD4+ and CD8+ T cells were mixed at a ratio of 3:1 
and a total of 107 cells were transferred i.p. to 8 week old NOD-Scid recipients.  Mice were 
monitored weekly for diabetes onset as described above.  Engraftment of donor T cells into the T 
cell deficient NOD-Scid hosts was confirmed by flow cytometry 80 days post transfer. 
2.3.16 Flow cytometry 
Peripheral blood samples were lysed with Gey’s solution twice and resuspended in 100 µl 
HBSS for staining.  Gey’s treated splenocytes, ficol separated bone marrow suspensions, or 
purified T cells were counted and resuspended in HBSS at 2 x 107 cells/mL.  Approximately 106 
cells were labeled with antibodies at the proper dilution.  Fluorescence was measured using LSR 
Fortessa (BD Bioscience, San Jose, CA).  Data were collected and analyzed using FACSDiva 6.0 
software (BD Biosciences). 
2.3.17 Statistics 
GraphPad Prism (GraphPad Software, Inc, (La Jolla, CA)] was used for calculating 
statistical differences.  Significance between mean values was determined using the Student’s t 
test or One-way ANOVA, with p < 0.05 considered significant.  Kaplan-Meier survival analysis 
was used to evaluate diabetes onset.   
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2.4 RESULTS 
2.4.1 No difference in ALR SOD1 cDNA, expression, or content; however increase dimer 
stability is linked with elevated antioxidant activity and maps to the Susp interval. 
It has previously been reported that ALR exhibits a constitutive and systemic elevation in 
the activity of SOD1 (112, 230), including that measured in liver (Fig. 2A).  However, 
sequencing of the cDNA did not identify any polymorphisms comparing ALR to control strains.  
Sod1 cDNA sequences from ALR, NOD, BALB, and B6 have been deposited in Genbank.  
Analysis of SOD1 mRNA expression and protein content also were not different in ALR (Fig. 
2B), suggesting post-translational modifications may be altering activity.  Therefore, the stability 
of the enzyme under reducing conditions was evaluated.  Red blood cell lysates were treated with 
DTT to disrupt the disulfide bridges required for dimerization or heated to 75°C, 85°C, or 95°C.  
SOD1 activity was visualized after treatment with NBT.  While there was no enhanced thermal 
stability of SOD1 derived from ALR or NOD-Susp compared to NOD (data not shown), SOD1 
from both ALR and NOD-Susp mice retained active SOD1 dimer after incubation with DTT 
(Fig. 2C), demonstrating increased stability of the enzyme to disulfide reduction.   
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Figure 2: Increased dimer stability is a feature of the ALR SOD1 isoform.  (A) Liver lysates SOD1 
activities.  (B) Western blot for SOD1 content.  (C) SOD1 dimer stability after treatment with DTT was visualized 
on a 12% non-denaturing acrylamide gel stained with NBT and riboflavin. 
 42 
2.4.2 Elevated SOD1 is reducing superoxide release after stimulation of bone marrow 
populations. 
Previous reports evaluating increased free radical scavenging and decreased ROS 
production inherent to the ALR have associated elevated SOD1 activity with decreased oxidative 
burst by neutrophil and macrophage NADPH oxidase (230), however none of these reports have 
directly linked these two phenotypes.  Similar to what we have measured in liver (Fig. 2A), bone 
marrow cells from both ALR and NOD-Susp exhibited increased SOD1 activity compared to 
bone marrow cells isolated from NOD [p<0.02 (Fig. 3A)].  The difference in SOD1 activity was 
ablated at KCN concentrations above 2mM that completely inhibited SOD1 activity (data not 
shown).  Oxidative burst was measured via cytochrome c reduction as well as oxygen 
consumption.  NOD bone marrow cells stimulated with PMA exhibit a robust burst with 
significant increases in cytochrome c reduction and oxygen consumption (Fig. 3B and 3C, 
respectively (black columns)).  After pre-treatment with the SOD1 inhibitor KCN (2mM) 
superoxide release from NOD cells was elevated as dismutation was blocked.  These elevations 
are lost when purified SOD1 is added back, confirming specificity for superoxide production.  
After stimulation with PMA, ALR cells demonstrate no increase in superoxide release (Fig. 3B), 
however, there was a significant increase in the oxygen consumed (Fig. 3C).  When SOD1 is 
inhibited with KCN, superoxide production is elevated after stimulation of bone marrow from 
ALR and NOD-Susp mice.  Specificity is confirmed by adding back SOD1 and by using a NOD 
congenic with a mutation that ablates NOX function (NOD-Ncf1) (184).  These data confirm that 
NOX function is likely intact in ALR monocytes and that the decreased secretion of superoxide 
in these cells from ALR mice results from elevated SOD1 activity and stability inherited with the 
Chr. 3 Susp locus.  
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Figure 3:  Elevated SOD1 activity is reducing release of superoxide by stimulated bone marrow cells 
in ALR.  (A) Bone marrow lysates were assayed for SOD1 activity.  Superoxide production was evaluated by 
measuring (B) rate reduction of cytochrome c and (C) oxygen consumption by PMA-stimulated bone marrow cells 
stimulated after inhibition of SOD1 with KCN.  Data representative of 3 independent experiments performed in 
triplicate. +p<0.02, # p<0.006, or * p< 0.0001. 
 
2.4.3 ALR Chr. 3 genomic contributions dominantly protect from overt diabetes and 
insulitis. 
Cohorts of NOD-Susp mice heterozygous or ALR homozygous on Chr. 3 were evaluated 
for T1D onset compared to littermate controls that were homozygous for NOD genome 
throughout the Susp interval.  Susp dominantly prevented both T1D and insulitis (Fig. 4).  NOD-
Susp females homozygous or heterozygous for ALR genome on Chr. 3 were 100% diabetes free 
out to 35 weeks of age, compared to only 25% of littermate controls (Fig. 4A).  NOD-Susp males 
were also completely diabetes resistant (data not shown).  Histological analysis of the mice that 
did not develop diabetes demonstrated no advancing insulitis in NOD-Susp congenic females 
compared to severe insulitis in the littermate controls (Fig. 4B).  Islets from NOD-Susp mice 
were also free of the accumulation of leukocytes compared to littermate controls that exhibited 
advanced insulitic infiltration (Fig. 4C). 
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Figure 4:  ALR Chr. 3 genome dominantly protects from T1D and insulitis.  (A) Age-matched female 
NOD-Susp(NOD) littermate controls, NOD-Susp(F1), and NOD-Susp(ALR) mice were monitored by glucosuria for 
the onset of spontaneous diabetes. (B) Insulitis scores in 40 week old non-diabetic mice. (C) Hemotoxylin and eosin 
staining of representative islets from mouse pancreata. 
2.4.4 NOD-Susp islets are not fully protected from proinflammatory-mediated damage 
To determine if diabetes resistance in NOD-Susp mice was conferred by enhanced 
pancreatic beta cell survival, islets from NOD.Rag, ALR, and NOD-Susp mice were isolated and 
treated with cytokines to evaluate cell viability and NO production.  Treatment with 
proinflammatory cytokines significantly reduced cell viability of NOD.Rag and NOD-Susp 
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cultured islets compared to ALR (Fig. 5A).  NOD-Susp islets produced NO after treatment with 
cytokines (Fig. 5B), demonstrating no change in the synthesis of reactive nitrogen species. 
To evaluate if beta cells demonstrated advanced survival in vivo to lysis mediated by 
autoreactive CD8+ T cells, sub-lethally irradiated NOD and NOD-Susp female mice were 
adoptively transferred with splenocytes from NOD-AI4a/b transgenic mice.  There was no 
significant difference in the rate or overall incidence of diabetes (Fig. 5C) as 66% NOD and 50% 
NOD-Susp mice developed diabetes by 15 days after adoptive transfer. 
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Figure 5: Susceptibility of islets to proinflammatory mediators.  Cultured islets from NOD.Rag, NOD-
Susp, and ALR mice were treated with cytokines, IFN-γ, IL-1β, and TNF-α.  Islets susceptibility to (A) 
proinflammatory cytokine-mediated damage and (B) induced NO production after treatment.  Data representative of 
3 independent experiments performed in triplicate.  (C) Splenocytes (2 x 107 cells) from NOD-AI4 donors were 
transferred to sub-lethally (7.5 Gy) irradiated NOD and NOD-Susp recipients.  Mice were considered diabetic after 2 
consecutive readings of blood glucose above 250 mg/dL.  ND not detected 
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2.4.5 NOD-Susp mice exhibit ALR-like elevation in SOD1 activity and reduction of NOX 
oxidative burst. 
NOD-Susp mice demonstrated elevated SOD1 activity (data not shown) similar to that of 
ALR, as well as reduced oxidative burst by stimulated macrophages (Fig. 6) and neutrophils 
(data not shown) as measured by superoxide-driven conversion of DHR123. 
 
Figure 6:  NOD-Susp congenic mice exhibit reduced oxidative burst.  Macrophages collected from bone 
marrow were stimulated with PMA.  ROS-driven conversion of DHR123 was monitored via flow cytometry. 
2.4.6 CD4+ and CD8+ T cells from NOD-Susp lose diabetogenic potential 
In addition to a defect in macrophage and neutrophil superoxide production, purified 
CD4+ T cells from NOD-Susp mice failed to produce superoxide after TCR crosslinking (Fig 
 49 
7A).  Previous genetic studies observed a co-dominant inheritance, witnessed with intermediate 
SOD1 activity and respiratory burst from heterozygous mice.  However, CD4+ T cells exhibit a 
complete loss of stimulated ROS production, suggesting that the modest elevation of SOD1 
dismutation is sufficient to eliminate superoxide produced.  As enhanced beta cell protection was 
not providing full protection (Fig. 5) and T cells lacked superoxide production after TCR 
crosslinking (Fig. 7A), the diabetogenic potential of the T cells was evaluated.    Purified CD4+ 
and CD8+ T cells from NOD and NOD-Susp donors were adoptively transferred to NOD-Scid 
recipients.  NOD-Susp T cells failed to induce diabetes as 100% of recipients were T1D-free, 
compared to 12% of controls (Fig. 7B).  Therefore, while Susp has a clear impact on myeloid 
cells, the role of this linkage in T1D resistance is due to a change in the autoreactive potential of 
T cells. 
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Figure 7:  NOD-Susp immune system fails to transfer T1D to immune deficient hosts.  T cell ROS 
production was measured by labeling purified CD4+ T cells with CM-H2DCFDA.  Cells were activated by adding 
hamster anti-mouse CD3 and then cross-linked with rabbit anti-hamster IgG.  Cells were analyzed at 0, 30, and 
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60min.  (A) ROS generation was determined by the increase in CM-H2DCFDA fluorescence upon anti-CD3 
stimulation over unstimulated control.  (B) Purified CD4+ and CD8+ T cells at a ratio of 3:1 (107 cells) from 8 week 
old prediabetic donor NOD and NOD-Susp female mice were transferred i.p. to NOD-Scid hosts.   
2.5 DISCUSSION 
The ALR mouse represents a unique model to study the impact of ROS scavenging as 
well as modulation of free radical production on type 1 diabetes development (227, 228, 232, 
233).  Elevated free radical defenses are linked with ALR islet resistance to free radical toxins, 
proinflammatory cytokines, and diabetogenic immune mediators.  Specifically, ALR exhibits a 
constitutive and systemic elevation in SOD1 activity, despite no observed differences in SOD1 
sequence, expression, or protein content (Fig. 2).  However, elevated SOD1 activity is associated 
with increased stability of the active homodimer.  After treatment with DTT, ALR SOD1 dimers 
remain active compared to controls, where dimer activity is lost due to the disruption of the 
necessary disulfide bridges.  This suggests that under stressful conditions, such as inflammation, 
ALR SOD1 stability may be enhanced resulting in continued SOD1 function. 
Previous reports described an inverse correlation of elevated hepatic SOD1 activity with 
decreased oxidative burst by neutrophil and macrophage NADPH oxidase (112, 230).  As 
increased SOD1 activity was also extended to bone marrow populations (Fig. 3A) we propose 
that increased superoxide dismutation was resulting in the suppression of superoxide production 
by immune cells, or at least in our ability to measure superoxide generation.  After PMA 
stimulation, ALR bone marrow cells demonstrate no measurable increase in superoxide release, 
however, there is a significant increase in the oxygen consumed (Fig. 3B and 3C) suggesting 
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oxygen was being converted to superoxide.  When SOD1 is inhibited with KCN, ALR 
superoxide production is elevated, demonstrating that NOX complex is functional in the ALR 
and that the reduction in superoxide being produced by the ALR cells results from the increased 
scavenging by SOD1.  This heightened free radical dismutation significantly alters the function 
of both innate and adaptive immune cells. 
Genetic segregation analyses localized Susp to Chr. 3 (112, 204).  To study the role of 
elevated SOD1 and reduced NOX in a T1D-prone model, the ALR-derived Susp locus was 
congenically introduced on the NOD background.  ALR genome on Chr. 3 was dominantly 
protective against T1D development as mice heterozygous and homozygous for Susp were 100% 
diabetes free, compared to littermate controls, which had an onset similar to that of NOD 
population (Fig. 4A).  Histological analysis of pancreata demonstrated little to no insulitis in 
congenic animals (Fig. 4B-C), suggesting there is a loss in the accumulation of leukocytes at the 
site of inflammation associated with ALR Chr. 3 genome.  The finding of an almost complete 
absence of insulitis was not expected, as the females of the parental ALR strain exhibit mild 
insulitis (112). 
While the congenic segment is large, encompassing ~92 Mbp on Chr. 3, these results 
demonstrate that ALR alleles provide significant modifications to diabetes susceptibility.  Within 
this region are several previously mapped loci including, Idd3, 10, 17, 18.  However, the IL-2 
allele, the candidate for Idd3, is identical in ALR and NOD (112), and the diagnostic markers for 
Idd 10, 17, and 18 are non-polymorphic comparing the strains, suggesting that the ALR-derived 
locus on Chr. 3 may be novel rather than resulting from alleles at Idd3, 10, 17, or 18.  Mice with 
smaller congenic segments will allow for further evaluation of T1D resistance provided by ALR-
derived Chr. 3 alleles. 
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To isolate the mechanism of protection to either the islet or immune system, islet viability 
after cytokine treatment was assessed.  While exhibiting slightly higher viability compared to 
NOD.Rag controls, NOD-Susp islets were not fully protected from cytokine-mediated damage as 
the ALR islets (Fig. 5A and (228, 232)).  Elevations in SOD1 activity are witnessed in pancreata 
of ALR mice and there are also decreases in other ROS and RNS sources.  Unlike ALR, after 
cytokine treatment NOD-Susp islets produced large amounts of NO, a potent contributor to beta 
cell toxicity (Fig. 5B). 
Type 1 diabetes is considered a T cell mediated disease.  In previous studies, ALR islets 
were demonstrated to resist destruction both in vivo and in vitro by autoreactive CD8 T cells 
(232).  To determine if the Susp region was associated with enhanced beta cell resistance to 
autoreactive cytotoxic T lymphocytes we performed adoptive transfer experiments using 
splenocytes from NOD mice transgenic for the diabetogenic AI4 T cell receptor (236).  In vivo, 
NOD-Susp islets did not demonstrate enhanced protection to inflammatory mediators as mice 
were susceptible to AI4 CD8+ T cells (Fig. 5C).  Therefore, Susp does not provide obvious 
resistance to T1D at the level of the pancreatic islet, and similar to the majority of the linkages 
associated with T1D, likely contributes to diabetes resistance through the modification of cells of 
the immune system. 
NOD-Susp congenic mice exhibited ALR-like elevation in SOD1 as well as decreased 
free radical production by immune cells, including neutrophils, macrophages (Figs. 3 and 6) and 
CD4+ T cells (Fig. 7A).  Therefore, the beta cell reactivity of NOD-Susp T cells was assessed via 
adoptive transfer to T1D-prone NOD-Scid recipients.  NOD-Susp immune cells failed to induce 
diabetes in a susceptible host demonstrating a loss of islet-directed autoreactivity (Fig. 7B).  
Taken together these data suggest that the protective role of this Chr. 3 linkage is by modulating 
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immune cell reactivity responsible for the aberrant immune response associated with beta cell-
directed autoimmunity. 
Free radical signaling is an important regulator of immune cell activation and cytokine 
synthesis (202, 207, 208, 210).  We have previously described a role for NOX superoxide 
production and antioxidant activity in directing proinflammatory cytokine production and 
diabetes susceptibility (202, 207, 208).  Evidence in animal models demonstrates a protective 
role for antioxidants, protecting islets from apoptosis, rejection, and autoimmunity (222, 224, 
225).  However, transgenic over-expression of antioxidants in beta cells via the rat insulin 
promoter has been less efficacious in preventing spontaneous T1D development (225, 237, 238), 
whereas systemic elevation of antioxidants has been effective in delaying or reducing T1D (202, 
210, 232, 239).  This suggests mechanisms other than islet-specific ROS scavenging were 
conferring resistance.  Specifically, modulation of immune reactivity most likely was accounting 
for decreased autoimmunity in these studies.  Our data suggests that the protection afforded by 
elevated SOD1 is not by significant enhancement of beta cell survival, but rather by modifying T 
cell reactivity.  The T1D protection witnessed in the NOD-Susp mice highlights an important 
role for antioxidant regulation of free radical signaling in immune cells and autoreactive T 
lymphocytes. 
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3.0  SUPEROXIDE PRODUCTION IS CRITICAL FOR THE INDUCTION OF 
AUTOREACTIVITY AND T1D 
This manuscript has been submitted for publication to Diabetes. 
3.1 ABSTRACT 
The role of reactive oxygen species (ROS) and their scavenging in the pathogenesis of 
Type 1 Diabetes (T1D) have garnered considerable controversy.  We previously linked 
decreased monocyte ROS with diabetes resistance in the ALR mouse, suggesting that free radical 
production by the immune system is important for diabetes.  NOD-Ncf1m1J mice with a genetic 
ablation of NOX activity had reduced and delayed T1D compared to NOD mice.  To determine 
the required cellular sources of ROS we used antibody depletion and adoptive transfer 
experiments.  After receiving treatment female mice were monitored for hyperglycemia and 
overt diabetes.  Depletion of macrophages and neutrophils fully protected NOD mice from T1D.  
However, elimination of neutrophils alone showed no significant reduction or delay in incidence, 
demonstrating that neutrophils are dispensable for T1D progression.  Induction of T1D in NOD-
Scid mice by adoptive transfer with diabetic NOD-Ncf1m1J splenocytes was significantly delayed 
compared to diabetic NOD splenocytes, suggesting macrophage ROS and modulation of effector 
responses are critical for T1D.  The adaptive immune response was also altered by the absence of 
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NOX activity, as purified T cells from NOD-Ncf1m1J mice failed to induce diabetes.  These data 
demonstrate that the impaired autoreactive response of NOX-deficient NOD-Ncf1m1J immune 
system results from an alteration in the APC-T cell axis rather than failure of neutrophils to act 
as effector cells.  
 
3.2 INTRODUCTION 
Destruction of pancreatic beta cells is mediated by aberrant immune responses to islet 
antigens leading to T1D.  During the early stages of disease, an insulitic infiltrate consisting of 
macrophages, dendritic cells (DC), T cells, and B cells accumulates in the pancreas (5, 6).  
Effector mechanisms, including direct T cell cytotoxicity and indirect methods mediated by 
leukocytes, contribute to beta cell destruction and overt diabetes.  Production of reactive oxygen 
species (ROS) has been proposed to be an important contributor to beta cell loss during T1D 
pathogenesis.  Endogenous free radicals produced by the beta cell in response to cytokines are 
one source of cytotoxic ROS.  IFN-γ in combination with IL-1β and TNF-α is cytotoxic to beta 
cells, due to increased production of nitric oxide and superoxide.  However, the roles of cellular 
sources of ROS during the development of spontaneous T1D have not been fully defined (133, 
176).  
NADPH Oxidase (NOX), a multi-component enzymatic complex, is a major source of 
free radicals and is important for the effector function of neutrophils and macrophages (141-
143).  Islet-infiltrating macrophages release high levels of ROS, including superoxide via NOX.  
Defects in NOX function have been associated with increased susceptibility to autoimmunity in 
 57 
experimental allergic encephalomyelitis and collagen-induced arthritis.  In addition to 
contributing to toxicity, free radicals are also potent signaling molecules and are important in 
adaptive immune responses (140, 177, 202, 208).  Recent work has demonstrated that exogenous 
as well as endogenous sources of ROS are involved in initiating and dictating cytokine responses 
of CD4+ T cells (Tse and Thayer, In Press) (176, 187, 190, 202).  Our findings in the ALR 
mouse suggest a role for increased free radical scavenging and reduced superoxide production in 
modifying diabetogenic reactivity of T cells.  NOD mice containing the ALR-derived Suppressor 
of superoxide production (Susp) locus are protected from T1D and T cells lose diabetogenic 
effector capabilities when transferred to susceptible hosts.  To study the role of superoxide 
production via NOX in a T1D-prone mouse model, independent of other ALR-derived 
phenotypes, a mutation in p47phox subunit was congenically introduced into the Non-obese 
diabetic (NOD) mouse (NOD-Ncf1m1J). 
Genetic ablation of NOX protects against T1D development, as NOD-Ncf1m1J mice have 
reduced incidence and delayed diabetes onset.  To determine the innate immune cellular sources 
of ROS essential for T1D pathogenesis, we depleted neutrophils and macrophages from NOD 
mice.  Here we show that macrophages are essential for T1D induction while neutrophils are 
dispensable.  Additionally, NOD-Ncf1m1J mice were protected from T1D after adoptive transfer 
of BDC-2.5 T cells, demonstrating a requirement of NOX during CD4+ T cell-mediated 
autoreactivity.  NOX-deficient beta cells were not fully protected as NOD-Ncf1m1J islets were 
susceptible to cytokine mediated damage and mice developed diabetes induced by AI4 CD8+ T 
cells.  We have previously shown that NOX function is important for T helper cell lineage 
development and cytokine synthesis (202, 207, 208).  Here we report the reduced diabetogenic 
capabilities of NOX-deficient leukocytes as purified splenocytes and T cells from NOD-Ncf1m1J 
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mice had delayed transfer kinetics of T1D in contrast to NOD mice.  Therefore, ROS production 
by macrophages and T cells is essential for the development and effector function of 
proinflammatory responses mediating beta cell destruction. 
3.3 METHODS 
3.3.1 Animals 
NOD/ShiLtJ, NOD.B6-Ncf1m1J/m1J [NOD-Ncf1m1J] mice were bred and housed in the 
University of Florida or the Children’s Hospital of Pittsburgh facility under specific pathogen-
free conditions.  NOD.CB17-Prkdcscid/J [NOD-Scid], C57BL/6-Ncf1m1J [B6-Ncf1] and 
C57BL/6.NOD-(D17Mit21-D17Mit10)/LtJ [B6-H2g7] mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME).  NOD.129S7 (B6)-Rag1tm1Mom/J [NOD.Rag], NOD.Cg-
Rag1tm1MomTg (TcraAI4)1Dvs/DvsJ [NOD-AI4a] and NOD.Cg-Rag1tm1MomTg 
(TcrbAI4)1Dvs/DvsJ [NOD-AI4b] were purchased from The Jackson Laboratory (Bar Harbor, 
ME) and bred in our mouse facility.  F1 hybrid progeny from matings of NOD-AI4a with NOD-
AI4b [NOD-AI4a/b] developed diabetes between 3-5 weeks of age.  All mice were housed in 
specific pathogen-free facilities and approved by the Institution Animal Care and Use Committee 
at the University of Florida or the Children’s Hospital of Pittsburgh.  
 59 
3.3.2 Materials 
Depleting antibodies anti-Gr1 [RB6-8C5] and anti-Ly6g [1A8] purchased from Bio X 
Cell (West Lebanon, NH) are both Rat IgG2 antibodies.  Fluorescently labeled antibodies, 
Pacific blue labeled anti-CD11b (M1/70), APC labeled anti-F4/80 (BM8), and PE labeled anti-
CD8 (53-6.7) were purchased from eBioscience (San Diego, CA).  PE labeled anti-Ly6G (1A8), 
APC labeled anti-CD11b (M1/70) and FITC labeled anti-CD11c (HL3) were purchased from BD 
Pharmingen (San Jose, CA).  Pacific blue labeled anti-CD4 (GK1.5) and APC/Cy7 labeled anti-
B220 (RA3-6B2) were purchased from Biolegend (San Diego, CA). 
3.3.3 Construction of the B6-H2g7-Ncf1m1J and NOD.Ncf1m1J mouse strains  
The spontaneous null allele Ncf1m1J (Chromosome 5) was congenically introgressed into 
the NOD genome to ablate NOX superoxide production by first generating F2 mice from 
outcrosses of B6-Ncf1m1J with B6-H2g7.  The subsequent B6.H2g7-Ncf1m1J mice were outcrossed 
and backcrossed to NOD for 10 generations.  To eliminate contaminating chromosomal 
segments, genotyping was performed by PCR amplification of 94 polymorphic microsatellite 
primers (Invitrogen) covering all 19 autosomes for the first six generations as described 
previously.  By N6 mice were homozygous for NOD genome at all loci save those in linkage 
with Ncf1 on Chr. 5.  From N6 until N10 genotyping was performed with markers on Chr. 5 
allowing for mice with the smallest possible congenic segment to be bred.  At N10 these marker-
assisted or “speed” congenic mice were intercrossed to generate mice that were homozygous for 
the Ncf1m1J allele. 
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DNA was obtained from murine tail biopsies as described previously.  Ncf1 exon 8-
specific PCR primers (forward: 5’-biotin-TAG AAA GGG AAA GCC AGA AAG AAT-3’, 
reverse: 5’-ACG CTT TGA TGG TTA CAT ACG GT-3’) were used to distinguish single 
nucleotide polymorphisms between the wild type allele and a mutation in the splice site of exon 
8 as previously described (172).  DNA sequencing was performed using pyrosequencing (PSQ 
96MA, Pyrosequencing, AB).  The pyrosequencing primer (5’-ACG CTT TGA TGG TTA CAT 
ACG GT-3’) was used for sequencing. Pyrosequence data were quantified and background 
corrected using PSQ 96MA version 2.0.2 software (Pyrosequencing, AB). 
3.3.4 Measurement of superoxide production 
Bone marrow was collected from age-matched NOD and NOD-Ncf1m1J female mice and 
red blood cells were removed on a Histopaque-1119 gradient as previously described (230).  In 
HBSS containing 145 μM cytochrome C, 1x105 cells were stimulated with PMA (98 nM) at 
37°C.  Reduction of cytochrome C was measured at 550 nm at 1 min intervals for 45 min.  The 
maximum rate of reduction was calculated by linear regression analysis.  Purified SOD1 (0.5 
U/mL) was used to confirm specificity of superoxide production. 
3.3.5 Measurement of oxygen consumption 
Bone marrow was collected from age-matched female mice and red blood cells were 
removed on a Histopaque-1119 gradient as previously described (230).  The Oxygraph-2K 
(Oroboros Instruments Innsbruck, Austria) was calibrated for basal oxygen levels with HBSS 
and after the addition of sodium hydrosulfite, following manufacturer’s instructions.  A total of 
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2x107 cells were pretreated with 2 mM KCN or HBSS for 15 min at room temperature.  Cells 
were resuspended in 2 mL HBSS and loaded into the chamber of the Oxygraph-2K at 37°C.  
Samples were stimulated with 1 µM PMA and oxygen concentration and rate of consumption 
were monitored for 30 min. 
3.3.6 Western immunoblotting 
Whole cell lysates were separated on a 4-20% gradient SDS-PAGE gel and transferred 
onto 0.45 µm charged PVDF membranes.  The membranes were incubated overnight at 4oC with 
antibodies against Stat4, Stat1α, T-bet, Stat3, or β-actin and exposed to the appropriate 
secondary antibody conjugated to horseradish peroxidase (Jackson ImmunoResearch).  
Chemiluminescence was detected with ECL plus (Amersham Pharmacia).  Image J software 
(National Institutes of Health) was used to generate densitometry data. 
 
3.3.7 Spontaneous incidence 
At 8 weeks of age, NOD and NOD-Ncf1m1J female mice were enrolled and monitored for 
diabetes onset with weekly urinalysis using Diastix [Bayer (Elkhart, IN)].  Mice positive for 
glucosuria were monitored daily thereafter for hyperglycemia using One Touch Ultra 2 meters 
[Life Scan, Inc (Milpitas, CA)].  Any mouse with measured blood glucose levels on consecutive 
days >250 mg/dL were diagnosed with type 1 diabetes. 
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3.3.8 Islet isolation and culture with cytokines 
Pancreatic islets from age-matched female NOD.Rag and NOD-Ncf1m1J isolated (235) 
and cultured with IFN-γ, IL-1β, and TNF-α as previously described (232).  Islet NO production 
was measured and cell viability was assessed via MTT assay as previously reported (228).  
3.3.9 Transfer of AI4 splenocytes 
At 3-4 weeks of age, NOD-AI4a/b donors were sacrificed and splenocytes were 
harvested.  After the red blood cells were lysed with Gey’s solution live cells were counted and 
diluted to a concentration of 108 cells per mL.  A total of 2 x 107 cells in sterile PBS were 
injected via the tail vein into sub-lethally irradiated eight week old NOD and NOD-Ncf1m1J 
females [dose of 7.5 Gy delivered using X-RAD 320 (Precision X-ray, North Branford, CT) as 
previously described.  Mice were monitored every other day for the onset of diabetes as 
described above. 
3.3.10 Transfer of BDC-2.5 T cell clones 
Cultures of BDC-2.5 T cells were collected and expanded in vitro as previously described 
(210) for adoptive transfer experiments.  NOD and NOD-Ncf1m1J mice were injected i.p. with 
107 BDC-2.5 T cells between 3-7 days of age.  Mice were monitored daily by urinalysis, using 
Diastix, for the onset of diabetes. 
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3.3.11 Adoptive transfer 
Diabetic (20 weeks old) or pre-diabetic (8 weeks old) NOD and NOD-Ncf1m1J donors 
were used for adoptive transfer experiments.  Splenocytes were harvested and red blood cells 
were lysed using Gey’s solution.  Splenocytes, 2 x 107 cells in PBS, were transferred i.p. to 8 
week old NOD-Scid recipients.  Additionally, CD4+ and CD8+ T cells were purified by negative 
selection with magnetic beads according to the manufacturer’s protocol using a CD4+ T cell 
isolation kit or a CD8+ T cell isolation kit (Miltenyi Biotec), respectively.  Purity, over 96%, was 
confirmed by flow cytometric analysis.  CD4+ and CD8+ T cells were mixed at a ratio of 3:1 and 
107 cells were transferred i.p. to 8 week old NOD-Scid recipients.  Mice were monitored weekly 
for diabetes onset as described above.  Engraftment of cells was confirmed by flow cytometry. 
3.3.12 Antibody depletion studies 
Depletion studies were initiated at 4 weeks of age and were carried out until the onset of 
T1D, as described above, or until 35 weeks of age.  Female NOD mice were treated i.p. with 
antibody diluted in sterile PBS three times per week.  The dose for either the anti-Gr-1 (RB6-
8C5) or anti-Ly6g (1A8) depleting antibodies was 500 µg on Monday and Wednesday as well as 
750 µg on Friday of each week (240).  The volume of all injections was 100 µL.  Depletion of 
macrophages and neutrophils in peripheral blood was confirmed monthly by flow cytometry.  
Bone marrow, splenocytes, and peripheral blood were analyzed via flow cytometry at sacrifice. 
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3.3.13 Flow cytometry 
Peripheral blood samples were lysed with Gey’s solution twice and resuspended in 100 µl 
HBSS for staining.  Gey’s treated splenocytes, ficol separated bone marrow suspensions, or 
purified T cells were counted and resuspended in HBSS at 2 x 107 cells/mL.  Approximately 106 
cells were labeled with antibodies at the proper dilution.  Fluorescence was measured using LSR 
Fortessa (BD Bioscience, San Jose, CA) and analyzed using FACSDiva 6.0 software (BD 
Biosciences). 
3.3.14 Statistics 
GraphPad Prism (GraphPad Software, Inc, (La Jolla, CA)] was used for calculating 
statistical differences.  Significance between mean values was determined using the Student’s t 
test, with p<0.05 considered significant.  Kaplan-Meier survival analysis was used to evaluate 
diabetes onset.   
3.4 RESULTS 
3.4.1 Ncf1 mutation ablates NOX superoxide production from bone marrow populations 
To study the role of ROS in the pathogenesis of T1D, we generated NOD mice with a 
genetic ablation of NOX superoxide production by congenic introduction of a mutant p47phox 
subunit (Ncf1) of NOX.  PMA stimulation of NOD bone marrow cells exhibited elevated 
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superoxide production (p<0.0001), however there was no increase in superoxide production after 
PMA stimulation of cells isolated from NOD-Ncf1m1J mice as measured by cytochrome c 
reduction (Fig. 8A) and oxygen consumption (Fig. 8B), confirming ablation of NOX function.  
Mice with the Ncf1m1J mutation had equal numbers of neutrophils (Ly6G+CD11b+)  (Figure 8C) 
and macrophages (Ly6G-CD11b+) (Figure 8E) when compared to Ncf1 intact mice of the same 
strain, but NOD, NOD-Ncf1m1J, and B6-H2g7 mice did exhibit reduced neutrophils when 
compared to B6 or ALR mice (Figure 8C).  Oxidation of DHR 123 to rhodamine was 
significantly absent in both neutrophils (Figure 8D) and macrophages (Figure 8F) from NOD-
Ncf1m1J and B6-H2g7-Ncf1m1J mice.  NOD and B6-H2g7 derived neutrophils and macrophages 
exhibited a normal oxidative burst.  The inability of neutrophils and macrophages to generate a 
sufficient respiratory burst in the NOD-Ncf1m1J mice was due to the absence of the p47phox 
protein.  Immunoblot analysis of whole cell lysates from purified macrophage and neutrophil 
(data not shown) cell populations demonstrated that the Ncf1 protein was absent in both cell 
types (Figure 8G). 
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Figure 8:  Ncf1m1J mutation decreases the respiratory burst.  Bone marrow from NOD and NOD-
Ncf1m1J mice was stimulated with PMA (98 nM).  (A) Superoxide production was evaluated by measuring rate 
reduction of cytochrome C .  Purified SOD1 (0.5 U/mL) was added to confirm production of superoxide.  (B)  
Oxygen consumption was measured with an oxygen electrode for 30 mins.  Results are from 5 independent 
experiments.  The percentage of bone marrow neutrophils (C) and macrophages (E) from C57BL/6.H2g7, 
C57BL/6.H2g7.Ncf1m1J, C57BL/6, ALR, NOD, and NOD.Ncf1m1J mice was assessed by flow cytometry with gating 
for macrophage- (Ly6G- CD11b+) or neutrophil-specific (Ly6G+ CD11b+) populations.  The respiratory burst 
capacity of bone marrow neutrophils (D) and macrophages (F) was assessed by loading 5x106 cells/mL with 0.99 M 
dihydrorhodamine and stimulated with 98 nM PMA for 40 minutes.  The oxidation of dihydrorhodamine to 
rhodamine was assessed by flow cytometry with gating for macrophage- (Gr1- CD11b+) or neutrophil-specific (Gr1+ 
CD11b+) populations.  (G) Whole cell lysates of cell sorted macrophages were used in an immunoblot analysis for 
p47phox and actin expression. 
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3.4.2 Ncf1 mutation ablates respiratory burst from T cells 
T cells express a p47phox containing NADPH oxidase and polyclonal anti-CD3 
stimulation elicits ROS production from primary T cells (181).  Targeted deletion of Ncf1 
eliminates T cell ROS production (181), therefore we tested if the Ncf1m1J allele also inhibited 
anti-CD3 stimulated ROS production from CD4+ T cells in the NOD mouse.  When purified 
CD4+ T cells from NOD mice were incubated with anti-CD3 there was a significant increase in 
ROS production by these CD4+ cells (Figure 9A).  In contrast, stimulation of NOD-Ncf1m1J 
CD4+ T cells did not lead to an increase in oxidation of the fluorescent indicator (Figure 9A).  
This lack of ROS production was not the result of low CD4+ T cell numbers as no differences 
were observed when comparing NOD and NOD-Ncf1m1J T cells (Figure 9B). 
 
 
Figure 9:  Ncf1m1J mutation decreases the respiratory burst capacity splenic T cells without 
decreasing the percentage of cells.  T cell ROS production was measured in by labeling purified CD4+ T cells with 
CM-H2DCFDA.  Cells were activated by adding hamster anti-mouse CD3 and then cross-linked with rabbit anti-
hamster IgG.  Cells were analyzed at 0, 30, and 60min.  (A) ROS generation was determined by the increase in CM-
H2DCFDA fluorescence upon anti-CD3 stimulation over unstimulated control.  (B) The percentage of splenic CD4+ 
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T cells was assessed by flow cytometry by gating for CD4+ T cell-specific populations (CD3+ CD4+ CD8-).  Results 
are representative of 3 independent experiments. 
3.4.3 Genetic ablation of NOX activity protects NOD congenic mice from T1D onset 
ROS synthesis is toxic to islet beta cells and also responsible for pathological 
complications associated with T1D, but whether ROS production is also necessary for initiating 
diabetogenesis and an autoimmune effector T cell response is not known.  To address these 
questions, spontaneous diabetes incidence of female NOD-Ncf1m1J mice in comparison to female 
NOD mice was determined.  At 40 weeks of age, 65% of female NOD-Ncf1m1J mice were 
euglycemic and diabetes-free, while only 15% of the age matched NOD females were 
euglycemic (Figure 10A).  Histological examination of pancreata from non-diabetic NOD mice 
at seven and twenty-two weeks demonstrated a significant increase in insulitis (Figure 10B, 
insulitis score: 0.55 ± 0.57 and 2.67 ± 0.68, respectively).  Immune infiltration into the islets did 
not advance with age in NOD-Ncf1m1J female mice (insulitis score: 7wk, 0.62 ± 0.54 and 22 wk, 
0.68 ± 0.62).  While the insulitis scores from 7 wk old NOD and NOD-Ncf1m1J mice did not 
differ, the insulitis was significantly increased (p<0.01) in 22 wk old NOD compared to age-
matched NOD-Ncf1m1J females.  Representative histology is presented in Figure 10C-2F. 
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Figure 10:  NOD-Ncf1m1J mice resist spontaneous diabetes.  (A) Kaplan-Meier survival curve of NOD 
(n=20) and NOD-Ncf1m1J (n=20) age-matched female mice for spontaneous diabetes incidence.  (B) Insulitis score 
of 7 and 22 week-old female NOD and NOD-Ncf1m1J mice.  Hemotoxylin and eosin staining of pancreatic sections 
from (C, E) 7 and 22 week-old female NOD and (D, F) NOD-Ncf1m1J mice.  Mice were diabetic after consecutive 
blood glucose readings of >300mg/dL. 
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3.4.4 Islets from NOD-Ncf1m1J mice exhibit no enhanced protection against 
proinflammatory cytokine toxicity 
To determine if the enhanced diabetes resistance in NOD-Ncf1m1J mice was due to the 
inherent inability of islets to generate ROS to promote pancreatic beta cell destruction, islets 
from NOD.Rag and NOD-Ncf1m1J mice were isolated and treated with cytokines to evaluate cell 
viability and NO production.  Treatment with proinflammatory cytokines significantly reduced 
cell viability of NOD.Rag and NOD-Ncf1m1J cultured islets (Fig. 11A).  NOX-deficient islets 
produced NO after treatment with cytokines (Fig. 11B), demonstrating no change in the 
synthesis of reactive nitrogen species. 
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Figure 11:  Cultured islets from NOD.Rag and NOD-Ncf1m1J mice were treated with cytokines IFN-γ, 
IL-1β, and TNF-α.  (A) Islets were susceptible to proinflammatory cytokine-mediated damage and (B) produced 
NO after treatment.  Data representative of 3 independent experiments performed in triplicate. 
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3.4.5 NOD-Ncf1m1J mice are susceptible to AI4 T cell transfer 
Intracellular production of ROS within islet cells contributes to beta cell killing (178, 
241-244), but whether the synthesis of ROS also functions as accessory molecules to facilitate T 
cell autoreactivity within the islet has not been well studied.  Beta cells express a phagocytic-like 
NOX complex that can produce superoxide upon stimulation (242, 244).  To determine if genetic 
ablation of NOX at the beta cell level would prevent diabetes induction with diabetogenic CD8+ 
T cells, we transferred highly pathogenic splenocytes from NOX-intact, NOD-AI4 transgenic 
donors to sub-lethally irradiated NOD and NOD-Ncf1m1J female mice.  There was no significant 
difference in the rate or overall incidence of diabetes (Fig. 12A) as 75% NOD and 75% NOD-
Ncf1m1J mice developed hyperglycemia 15 days after adoptive transfer. 
3.4.6 NOD-Ncf1m1J mice are resistant to BDC-2.5 T cell transfer 
In addition to their function in perpetuating cytotoxic responses, macrophages also serve 
as vital antigen presenting cells.  Depletion or inactivation of phagocytes and macrophages has 
prevented diabetes progression in mouse and rat models (27, 245-247) and recent reports suggest 
that macrophages are essential for T cell autoreactivity in the BDC-2.5 transfer models (24, 28, 
248).  To determine if the absence of phagocyte ROS production is essential for mediating type 1 
diabetes resistance in the NOD-Ncf1m1J mouse, we transferred BDC-2.5 T cells (210) to NOX 
deficient NOD-Ncf1m1J mice.  CD4+ T cells from BDC-2.5 transgenic mice were transferred into 
age-matched NOD and NOD-Ncf1m1J female recipients.  All NOD recipients developed diabetes 
5 days post transfer, however; thirty days following, NOD-Ncf1m1J mice had still not developed 
diabetes (Fig. 12B).   
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Figure 12:  AI4 transgenic T cells, but not BDC-2.5 cells are able to induce diabetes in NOX-deficient 
mice.  (A) Splenocytes (2 x 107 cells) from NOD-AI4 donors were transferred to sub-lethally (7.5 Gy) irradiated 
NOD and NOD-Ncf1m1J recipients. (B) BDC-2.5 CD4+ T cells were harvested, activated and transferred to age 
matched NOD and NOD-Ncf1m1J recipients. Mice were monitored by glucosuria for the onset of diabetes.  Mice 
were considered diabetic after 2 consecutive readings of blood glucose above 250 mg/dL.    
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3.4.7 Macrophages are essential while neutrophils are superfluous for type 1 diabetes 
pathogenesis 
NOX respiratory burst is well described in neutrophils and macrophages and is an 
important mechanism by which these innate immune cells mediate killing (18, 141-143).  
Macrophages have previously been reported as critical to the development of spontaneous T1D, 
as specific depletion prevents T1D development (249-252); however direct assessment of 
neutrophils has not been investigated.  To elucidate the involvement of neutrophils in type 1 
diabetes pathogenesis, the use of Gr-1-specific monoclonal antibodies, RB6-8C5 and 1A8, were 
utilized for depletion studies.  RB6-8C5 clone binds to Ly6G and Ly6C, while 1A8 is Ly6G 
specific.  NOD female mice were treated with either RB6-8C5 antibodies to deplete 
macrophages and neutrophils, 1A8 antibodies to deplete only neutrophils (240).  Depletion with 
RB6-8C5 provided 100% protection from diabetes development, while treatment with 1A8 only 
provided no protection from type 1 diabetes after 35 weeks as compared to control treated 
animals (Fig. 13A).  Weekly systemic administration of the antibodies began at 4 weeks of age, 
prior to advancing insulitis, and continued throughout the course of the study to maintain 
reduction of the target cell types.  Peripheral blood samples were collected monthly and 
monitored via flow cytometry to determine depletion of macrophages (CD11b+F4/80+) and 
neutrophils (CD11b+Ly6G+).  Over the course of the study, RB6-8C5 substantially depleted both 
macrophage and neutrophil populations (Fig. 13B-D, center panel) while 1A8 only depleted 
neutrophils with no significant affect on macrophage numbers (Fig. 13B-D, right panel).  
CD11b+ cells were gated and analyzed for F4/80 and Ly6G expression.  Representative samples 
from 16 week old mice are shown in Fig. 13D.  There were no changes in dendritic cell or 
lymphocyte populations from either treatment (data not shown). 
 76 
 
Figure 13 Macrophages but not neutrophils are critical for type 1 diabetes induction.  (A)  Age-
matched NOD female mice were treated with 500 ug 2 days a week and 750 ug 1 day a week anti-Gr-1 RB6-8C5, 1 
mg 3 days a week with anti-Gr-1 1A8, or PBS vehicle control starting at 4 weeks of age. Mice were monitored by 
glucosuria for the onset of diabetes and considered diabetic after 2 consecutive readings of blood glucose above 250 
mg/dL.  Peripheral blood was used to confirm depletion of (B) neutrophils (CD11b+Ly6G+) and (C) macrophages 
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(CD11b+F4/80+) by flow cytometry.  Blood samples were gated on CD11b+ cells and analyzed for Ly6G and F4/80 
expression (representative plot of treated mice at 16 weeks of age) (D).  Statistical differences noted above signify: * 
p< 0.0001 or # p<0.002, respectively. 
3.4.8 Delayed transfer of diabetes with NOD-Ncf1m1J splenocytes and purified CD4+ and 
CD8+ T cells 
To assess internal defects in the diabetogenicity of APC and T cells lacking intracellular 
superoxide production, whole splenocytes or purified T cells collected from diabetic and pre-
diabetic female NOD and NOD-Ncf1m1J donors were adoptively transferred into NOD-Scid 
recipients.  Splenocytes from diabetic (Figure 14A) and prediabetic (Figure 14B) NOD-Ncf1m1J 
mice exhibited delayed diabetes onset compared to NOD cells.  As the phagocyte NADPH 
Oxidase is expressed in T cells and activated after T cell receptor stimulation, we also sought to 
determine if NOX-deficient T cells would lack the ability to transfer disease.  To study potential 
defects specifically in NOX-deficient T cells, CD4+ and CD8+ T cells from donor animals were 
purified and adoptively transferred into NOX-intact NOD-Scid recipients.  A significantly 
delayed transfer of disease was observed in hosts receiving NOD-Ncf1m1J purified T cells 
(Figure 14C) compared to transfer with NOD donor T cells. 
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Figure 14:  The NOX-deficient NOD-Ncf1m1J immune system has a reduced capacity to transfer type 
1 diabetes to immune deficient hosts.  Splenocytes (2 x 107 cells) from (A) 20 week old diabetic or (B) 8 week old 
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prediabetic donor NOD and NOD-Ncf1m1J female mice were transferred i.p. to NOD-Scid hosts.  (C) A total of 107 
purified CD4+ and CD8+ T cells at a ratio of 3:1 were transferred i.p. to NOD-Scid recipients.  In all three transfer 
experiments mice were monitored by glucosuria for the onset of diabetes and confirmed by blood glucose 
measurement.  Mice were considered diabetic after 2 consecutive readings of blood glucose above 250 mg/dL. 
3.5 DISCUSSION 
Free radical generation, either exogenous or endogenous to the beta cell, is thought to 
contribute to beta cell demise and diabetes (210, 227, 228, 232).  Oxidative stress and the 
generation of free radicals are directly toxic to beta cells, but they also have a dual role as potent 
signaling molecules to induce pro-inflammatory cytokine synthesis that can also directly impact 
beta cell destruction.  Genetic analyses investigating diabetes resistance in the ALR mouse 
linked increased free radical scavenging and decreased ROS production with T1D protection 
(112, 133, 230).  NOD-Ncf1m1J mice were generated to evaluate the role of superoxide 
production in the pathogenesis of T1D in the diabetes-prone NOD mouse model.  Genetic 
ablation of NOX-mediated superoxide production (Fig. 8-9) was significantly protective when 
congenically introgressed into the NOD genetic background (Fig. 10).  Inhibition of NOX 
activity had a positive impact on diabetes development.  NOD-Ncf1m1J female mice exhibited a 
significant reduction (35% in NOD-Ncf1m1J versus 85% in NOD; P<0.0003) and delay 
(P<0.0001) in autoimmune diabetes development compared to female NOD mice (Fig. 10A).  
The delay in T1D was mirrored by a slower insulitis progression in NOD-Ncf1m1J pancreata (Fig. 
10B).  Insulitis scores for both NOD and NOD-Ncf1m1J were equal at 7 weeks of age.  A 
significant divergence (P<0.01) was observed comparing NOX deficient NOD mice at 22 weeks 
of age to non-diabetic wild-type NOD females.  This lack of advance in insulitic damage signals 
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a delay in the switch from peripheral to invasive insulitis.  Therefore, NOX activity and ROS 
production is important for T1D onset and it is required for insulitis progression. 
Recent work suggests NOX complex subunits are expressed in beta cells and produce 
superoxide upon stimulation (242-244).  In the absence of beta cell-specific ROS synthesis, 
NOD-Ncf1m1J cultured islets were still susceptible to cytokine-mediated cell death (Fig. 11A) 
and capable of producing NO in response to cytokines (Fig. 11B), demonstrating no defect in the 
production of reactive nitrogen species.  NOD-Ncf1m1J mice were equally susceptible as NOD 
mice to diabetes induction with AI4 splenocytes (Fig. 12A), a highly diabetogenic CD8+ T cell.  
Pre-activated AI4 CD8 T+ cells are efficient effectors, capable of inducing T1D without 
leukocyte help (236, 253).  These results demonstrate that NOX-deficient beta cells are 
susceptible to immune-mediated destruction.   
Macrophage and neutrophil production of superoxide via NOX is an important 
mechanism employed during immune responses and is a significant source of ROS during 
inflammation.  Macrophages have been shown to be important in the pathogenesis of T1D (24, 
27, 28, 245, 246) however, neutrophils have not been as extensively studied.  The contributions 
of ROS-producing innate immune cells to T1D pathogenesis were investigated with depleting 
antibodies specific for macrophages and neutrophils (RB6-8C5) or neutrophils alone (1A8) 
(240).  When both macrophage and neutrophil populations were depleted, 100% of the animals 
were free of T1D out to 35 weeks; however, neutrophil depletion alone did not alter the course of 
T1D development (Fig. 13).  While neutrophils may be involved in beta cell killing and 
autoreactivity, effector contributions are not essential and may be redundant in the process of 
beta cell damage.  Both neutrophils and macrophages exhibit important phagocytic and direct 
cytotoxic effector function, but macrophages are also involved in antigen presentation and 
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stimulation of T cells.  The protection afforded by NOX inhibition may partially be explained at 
the macrophage level as observed with the adoptive transfer studies with BDC-2.5 CD4+ T cells 
into NOD-Ncf1m1J recipients (Fig. 12B).  Whereas AI4 CD8+ T cells are preactivated in the host 
and can elicit beta cell-specific cytolytic effector function when transferred to a recipient, BDC-
2.5 CD4+ T cells require macrophages.  Reports by Calderon et al. show that macrophages are 
essential for effector function and diabetes induction in BDC-2.5 transfer models (24, 248).  Our 
data suggests that NOX-deficient macrophages are unable to mediate pancreatic beta cell 
destruction after adoptive transfer with BDC-2.5 T cells.  Taken together, not only are 
macrophages required, but NOX-dependent ROS production by macrophages are likely essential 
for CD4+ T cell effector function and autoreactivity. 
Diabetogenic defects resulting from NOX ablation were assessed by adoptive transfer of 
whole splenocytes or purified T cells collected from diabetic and pre-diabetic female NOD and 
NOD-Ncf1m1J donors.  Adoptive transfer experiments demonstrated delayed transfer kinetics to 
NOX-intact hosts (Fig 14A-C), suggesting a defect intrinsic to the NOX-deficient T cell.  This 
delay occurred with the transfer of whole splenocytes and with purified CD4+ and CD8+ T cells, 
where antigen presentation would be in the context of a NOX-intact host APC.  Transfer with 
splenocytes harvested from diabetic donors, where the islet-reactive population would be 
expanded and activated, was still delayed compared to control NOD donor cells.  This finding 
demonstrates a fundamental defect in the ability of NOX-deficient leukocytes to respond and 
execute sufficient effector function.  It also shows that ROS production by the T cell is essential 
for initiating islet-directed autoimmunity.  Redox status and redox molecules are important 
contributors to transcriptional and post-transcriptional regulation of transcription factors and 
cytokine synthesis (139, 204, 254).  Th1 IFN-γ activity is implicated in the aberrant 
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autoreactivity mediating beta cell destruction (44, 255) and T1D, and deviations in the cytokine 
profile can be protective (80-82).  We have previously shown that redox balance and superoxide 
production are critical in the initiation of a pathogenic cytokine response (184, 202, 207, 208, 
256).  The adoptive transfer experiments with pre-diabetic T cells alone demonstrated that in the 
absence of intrinsic ROS production there is decreased islet reactivity.  Therefore, we propose 
that T1D is reduced and delayed by the Ncf1m1J mutation as a result of inefficient Th1 T cell 
activation and differentiation. 
Our data describe a role for ROS produced by macrophages and T cells in the initiation of 
autoimmune diabetes.  Macrophage ROS-mediated effector function is essential for CD4+ T cell 
autoreactivity and T1D pathogenesis.  Additionally, intracellular ROS produced by the T cell is 
important for executing efficient islet reactivity.  The loss of ROS synthesis provided by the Ncf1 
mutation significantly alters effector function of macrophages and T cells.  This demonstrates the 
importance of ROS-dependent mechanisms in controlling activation of autoimmune effectors 
and in turn mediating aberrant reactivity towards beta cells. 
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4.0  NADPH OXIDASE DEFICIENCY REGULATES T HELPER LINEAGE 
COMMITMENT AND AUTOIMMUNITY 
This manuscript was accepted for publication in the Journal of Immunology.  Dr. Hubert Tse 
(Department of Microbiology, University of Alabama) and Terri Thayer (Immunology Graduate 
Program) are co-first authors, having generated the majority of the data and prepared the 
manuscript. 
4.1 ABSTRACT 
Reactive oxygen species (ROS) are used by the immune system to eliminate infections; 
however they may also serve as signaling intermediates to coordinate the efforts of the innate 
and adaptive immune systems.  In this study, we show that by eliminating macrophage and T cell 
superoxide production through the NADPH Oxidase (NOX), T cell polarization was altered.  
After stimulation with immobilized anti-CD3 and anti-CD28 or priming recall, T cells from 
NOX-deficient mice exhibited a skewed Th17 phenotype, whereas NOX-intact cells produced 
cytokines indicative of a Th1 response.  These findings were corroborated in vivo by studying 
two different autoimmune diseases mediated by Th17 or Th1 pathogenic T cell responses.  
NOX-deficient Non-Obese Diabetic (NOD) mice were Th17 prone with a concomitant 
susceptibility to experimental allergic encephalomyelitis and significant protection against Type 
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1 Diabetes (T1D).  These data validated the role of superoxide in shaping T helper responses and 
as a signaling intermediate to modulate Th17 and Th1 T cell responses. 
 
4.2 INTRODUCTION 
Type 1 diabetes (T1D) is an autoimmune disease with a prevalence of approximately 1% 
with an incidence that is increasing at a rate of 3% per year.  While T1D is one of the most 
common chronic diseases of childhood, there is no cure for this disease and the pathogenic 
mechanisms of the human condition remain unidentified.  Persistent evidence demonstrates that 
Th1 T cell responses and the synthesis of pro-inflammatory cytokines and reactive oxygen 
species (ROS) are essential for beta cell destruction in T1D (178, 210, 232, 248).  The exact role 
of ROS in T1D appears to be complex, and whereas these molecules have been linked to beta 
cell killing, a role for these molecules at the level of the immune response has not been firmly 
established. 
ROS are not only the first line of defense of innate immune effectors in response to 
invading pathogens, but they also function as both intra- and intercellular signaling molecules for 
the induction of pro-inflammatory cytokine synthesis.  The combined action of innate immune-
derived pro-inflammatory cytokines and ROS modulates adaptive immune function.  A potential 
major source of ROS in immune signaling in both Antigen Presenting Cells (APC) and T 
lymphocytes is the NADPH Oxidase (NOX).  Recent evidence has demonstrated, via the genetic 
ablation of an essential subunit of NOX, Cybb (gp91phox), the importance of NOX activity in 
skewing T helper responses during the response to a fungal infection (257, 258).  Whereas 
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extracellular ROS appears to control T cell reactivity, T lymphocytes do express a phagocyte-
type NOX and this complex functions in T cells to produce ROS in response to stimulation via 
the T Cell Receptor (TCR) (181). 
The absence of reactive oxygen species in T cells has also been demonstrated to be 
associated with an increase in the severity of antigen-induced experimental allergic 
encephalomyelitis (EAE) and collagen-induced arthritis (171, 172, 259, 260).  In contrast, our 
previous genetic mapping studies using T1D-prone NOD with T1D-resistant ALR mice linked 
resistance against spontaneous autoimmune diabetes, reduced oxidative burst from neutrophils 
and macrophages, as well as elevated Superoxide Dismutase 1 (SOD1) activity to the Suppressor 
of Superoxide Production (Susp) locus on Chr. 3 (112, 230).  Congenic replacement of Chr. 3 
Susp locus in the NOD provided 100% protection from T1D and was associated with decreased 
autoreactivity of T lymphocytes (Chapter 2).  To study the impact of ablated NOX activity on the 
development of spontaneous autoimmune diabetes, in the absence of high SOD1 activity, we 
generated NOD mice with a spontaneous mutation in the Neutrophil Cytosolic Factor 1 (Ncf1) 
gene (Chapter 3).  The Ncf1m1J mutation is a point mutation in exon 8 that results in an aberrant 
mRNA splicing event and terminal truncation of the p47phox subunit, preventing NOX assembly 
and superoxide synthesis (171, 172, 259, 260).  This mutation was also associated with reduced 
T1D incidence and inefficient diabetes transfer with NOX-deficient lymphocytes. 
Here, we report a role for superoxide in modulating immune responses.  NOX-deficiency 
altered redox-dependent innate immune cytokine synthesis, observed as reductions in TNF-α, IL-
1β, and IL-12 p70 while IL-23, a cytokine necessary for driving Th17 differentiation (261), was 
elevated.  In addition, polyclonal or antigen-induced activated T cells from NOD-Ncf1m1J mice 
exhibited a decreased Th1 cytokine response, and instead demonstrated a cytokine profile 
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reminiscent of a Th17 response.  These immune polarizations were strongly correlated with the 
immune responses in the whole animal as NOX-deficiency attenuated T1D while promoting 
development of the prototypical Th17 disease, EAE.  These data demonstrate the importance of 
superoxide in shaping immune responses. 
 
4.3 METHODS 
4.3.1 Animals 
NOD/ShiLtJ, ALR/LtJ, and NOD.B6-Ncf1m1J (NOD-Ncf1m1J) mice were bred and housed 
under specific pathogen-free conditions in the Animal Facility of the Rangos Research Center in 
the University of Pittsburgh.  B6.NOD-(D17Mit21-D17Mit10) [B6-H2g7], B6(Cg)-Ncf1m1J/J (B6-
Ncf1m1J), and SJL/J mice were purchased from The Jackson Laboratory (Bar Harbor, ME).  
Female mice at 6 to 8 weeks of age were used in all experiments except for the EAE induction, 
where 6-week-old males were used. 
4.3.2 Materials 
Anti-IL-2 and anti-IFNγ antibody pairs for ELISAs, as well as CD3, CD4, CD8, CD90.2, 
Ly6g (Gr1), and CD11b fluorochrome-conjugated antibodies were purchased from Pharmingen 
(San Diego, CA).  Hen egg lysozyme (HEL), anti-β-actin monoclonal antibody, CM-H2DCFDA, 
and 4-alpha-phorbol-12-myristate-13-acetate (PMA) were purchased from Sigma (St. Louis, 
 87 
MO).  Dihydrorhodamine 123 (DHR123) was purchased from Invitrogen (Carlsbad, CA).  
Antibodies against p47phox, the gene product of Ncf1, and phospho-Stat3 were purchased from 
Cell Signaling (Danvers, MA).  Antibodies against Stat4 and T-bet were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA).  The anti-Stat1α antibody was purchased from Zymed 
(San Francisco, CA). 
4.3.3 Flow cytometry 
Splenic leukocytes were harvested and washed twice in FACS buffer (1% BSA in PBS), 
counted, and resuspended in a final concentration of 2x107 cells/mL in FACS buffer.  One 
million cells were stained with directly fluorochrome-conjugated Abs purchased from either 
eBioscience or BD Biosciences.  The antibodies [PE-labeled anti-Ly6g (Gr1), APC-labeled anti-
CD11b, Pacific blue-labeled anti-CD4, APC-labeled anti-CD25, PE-labeled anti-FoxP3, FITC-
labeled anti-CD8, PECy5-labeled anti-CD4, PE-labeled anti-CD62L, PerCpCy5.5-labeled anti-
CD69, and APC-Cy7-labeled anti-CD44, FITC-labeled anti-IFNγ, and PE-labeled anti-IL-17A] 
were used at the appropriate dilution (10 µL of each Ab) and fluorescence was measured using a 
LSRII (BD Biosciences).  Results were analyzed with Cellquest software (BD Biosciences). 
4.3.4 Measurement of intracellular ROS by flow cytometry 
Neutrophil and macrophage superoxide production were assayed using FACS as 
previously described (230).  Briefly, bone marrow was isolated and purified using a Ficoll 
gradient.  Cells were labeled with PE-labeled anti-Ly6g (Gr1) and APC-labeled anti-CD11b and 
then loaded with Dihydrorhodamine 123 (DHR 123) for 5 minutes at 37°C.  Cells were subjected 
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to flow cytometry prior to stimulation, and then at 5-minute intervals after 98 nM PMA 
stimulation.  The ROS driven conversion of DHR 123 to rhodamine was measured using a 
FACSCalibur.  Ly6g and CD11b extracellular markers were used to discriminate neutrophils 
(Ly6G+, CD11b+) and macrophages (Ly6G-, CD11b+) from other bone marrow cells, and results 
were analyzed with Cellquest software (BD Biosciences). 
4.3.5 Isolation of mouse bone marrow-derived macrophages 
Bone marrow-derived macrophages were cultured as described previously (256) and 
plated on 6- and 24-well tissue culture plates and 100 mm petri dishes at concentrations of 4 x 
106 cells/well, 106 cells/well, or 2.4 x 107 cells/dish, respectively.  Macrophages were stimulated 
with 100 ng/mL of LPS from E. coli (055:B5) (Sigma Aldrich). 
4.3.6 Plate bound anti-CD3 and anti-CD28 activation of purified CD4+ T cell and cell 
lysates 
Splenic CD4+ T cells were purified by negative selection with a CD4+ T cell isolation kit 
(Miltenyi Biotec) supplemented with biotinylated mouse anti-rat RT1B (OX-6) Ab.  Naïve 
CD4+CD62L+ T cells were purified with a CD4+CD62L+ T cell Isolation kit (Miltenyi Biotec) by 
following manufacturer’s protocol.  5x105 purified splenic T cells were stimulated with anti-
CD3ε and anti-CD28 Ab at concentrations of 0.1 µg/mL and 1 µg/mL, respectively, for 72 hr 
(256).  Supernatants were harvested for cytokine analysis, T cell proliferation, and whole cell 
lysates were prepared as described previously (256). 
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4.3.7 Cytokine measurements by ELISA and Luminex 
IL-2, IFNγ, IL-12 p70, IL-17, TNFα, and IL-1β were detected with DuoSet ELISA kits 
(R&D Systems) or with Ab pairs from BD Pharmingen.  TGFβ was measured using a TGFβ 
Quantikine kit from R&D Systems.  ELISA plates were read on a SpectraMax M2 microplate 
reader and analyzed using Softmax Pro v.5.0.1 (Molecular Devices Corp.).  Additionally, 
cytokine levels in culture supernatants were quantified using the Bio-Plex™ multiplex 
suspension array system and a mouse cytokine/chemokine panel (Bio-Rad).  The concentrations 
of each sample were determined using Bio-Plex Manager Version 3.0 software.  NO2- was 
measured by the Greiss assay as described previously (256). 
4.3.8 qRT-PCR 
Bone marrow-derived macrophages were stimulated 4 hours with LPS.  RNA was 
isolated with TRIzol and cDNA prepared by SuperScript III (Invitrogen).  SYBR Green reagent 
(BioRad) was used for quantitative RT-PCR analyzed on a LightCycler 480 II (Roche) with 
forward and reverse primers specific for Xbp1, Hspa5 (BIP), Chop, and Actin as adapted from 
(262). 
4.3.9 Immunization of mice, antigen-recall and criss-cross assays 
Mice were injected with 100 µg of HEL in CFA subcutaneously at the base of the tail.  
Seven days after immunization, mice were sacrificed and the inguinal and periaortic lymph node 
(LN) were harvested for in vitro antigen recall assays as described previously (202).  Antigen-
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recall assays were set up by stimulating LN single cell suspensions with 25 µg of HEL in 
complete DMEM and supernatants were harvested for cytokine analysis at 48, 72, and 96 hours.  
For antigen-recall criss-cross assays, LN single cell suspensions were split into two groups and 
used to purify T cell and antigen-presenting cells by negative selection.  CD4+ T cells were 
purified by negative selection with a CD4+ T cell isolation kit (Miltenyi Biotec) supplemented 
with biotinylated mouse anti-rat RT1B (OX-6) Ab according to the manufacturer’s protocol.  
Antigen-presenting cells were purified by negative selection with anti-CD4 and anti-CD8 
antibodies conjugated to magnetic beads over a LS column (Miltenyi Biotec). 
4.3.10 Intracellular cytokine staining 
Intracellular IFN-γ and IL-17A was measured after polyclonal stimulation of naïve 
CD4+CD62L+ T cells.  Stimulated cells were treated with GolgiStop for 5 hours at 37 oC in a 5% 
CO2 humid air incubator with the aid of the murine BD intracellular cytokine staining kit (BD 
Biosciences) according to the manufacturer’s protocol.  After stimulation, cells were surface 
stained with PECy5-labeled anti-CD4, fixed in BD Cytofix/Cytoperm buffer, washed in BD 
Perm/Wash buffer, and then stained with FITC-labeled rat anti-IFN-γ (XMG1.2; BD 
Biosciences) and PE-labeled rat anti-IL-17A (TC11-18H10; BD Biosciences) and isotype 
controls according to the manufacturer’s protocol.  Cells were washed twice in BD Perm/Wash 
buffer, resuspended in FACS buffer, and stained cells were analyzed on a BD Fortessa.  Results 
were analyzed with FACSDiva software (BD Biosciences). 
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4.3.11 Western immunoblotting 
Whole cell lysates was separated on a 4-20% gradient SDS-PAGE gel and transferred 
onto 0.45 µm charged PVDF membranes.  The membranes were incubated overnight at 4oC with 
antibodies against Stat4, Stat1α, T-bet, Stat3, or β-actin and exposed to the appropriate 
secondary antibody conjugated to horseradish peroxidase (Jackson ImmunoResearch).  
Chemiluminescence was detected with ECL plus (Amersham Pharmacia).  Image J software 
(National Institutes of Health) was used to generate densitometry data. 
 
4.3.12 Induction of EAE 
Eight week old SJL, NOD, and NOD-Ncf1m1J were treated with 100µg MOG35-55 in CFA 
by subcutaneous injection in the base of tail.  Mice were also treated i.p. with 200ng Pertussis 
toxin on day 0 and day 2.  Mice were evaluated three days a week for symptoms following the 
standard five-point scale: 0, asymptomatic; 1, limp tail; 2, hind limb weakness/ incomplete limb 
paralysis; 3, complete hind leg paralysis; 4, complete hind and partial front leg paralysis; 5, 
moribund (263, 264). 
4.3.13 Statistical analysis 
Determination of the difference between mean values for each experimental group was 
assessed by the Student’s t test, with p<0.05 considered significant.  All experiments were 
performed at least three separate times with data obtained in triplicate wells in each experiment. 
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4.4 RESULTS 
4.4.1 NOD-Ncf1m1J T cells exhibit a skewed cytokine response from Th1- to a Th17-like 
phenotype 
Recent evidence has demonstrated that T cells express a phagocyte type NADPH oxidase 
that is vital for TCR signaling upon CD3 and CD28 cross-linking (181), therefore, we 
hypothesized that NOX-deficient NOD mice would have decreased T cell receptor signaling and 
subsequent adaptive immune effector function.  Immunoblot analysis of whole cell lysates from 
anti-CD3 and anti-CD28-stimulated NOD and NOD-Ncf1m1J T cells demonstrated that only 
NOD-Ncf1m1J T cells lacked p47phox expression (Figure 15A) similar to bone marrow-derived 
macrophages (Figure 8G).  The Ncf1 mutation in NOD T cells also had a profound effect on 
cytokine synthesis as plate-bound anti-CD3 and anti-CD28 cross-linking of purified NOD-
Ncf1m1J T cells exhibited a 3-fold decrease in proliferation, IL-2, and IFNγ secretion (Figure 
15B-D) in comparison to NOD T cells.  Interestingly, these polyclonal-stimulated T cells 
demonstrated a T cell response reminiscent of a Th17-like phenotype.  NOD-Ncf1m1J T cells 
synthesized 2-fold decrease in TNFα, 3-fold more IL-17, 40-fold increase in TGF-β, 2-fold 
increase in IL-10, equivalent IL-6 levels, 2-fold decrease in IL-4, and a 2.5-fold decrease in GM-
CSF levels compared with NOD T cells upon polyclonal stimulation (Figure 15E-K).  
Additionally, intracellular cytokine staining of polyclonal stimulated naïve CD4+CD62L+ T cells 
(Figure 16) from NOD and NOD-Ncf1m1J mice was performed.  No differences were observed in 
naïve (CD4+CD62L+CD69-CD44-), effector (CD4+CD62L-CD69+CD44+), and memory 
(CD4+CD62L-CD69-CD44+) splenic CD4+ T cell subsets from 8-wk-old age-matched NOD and 
NOD-Ncf1m1J female mice by flow cytometry (Figure 16A).  Naïve NOD-stimulated T cells 
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exhibited a 1.5-fold increase in the percentage of CD4+/IFN-γ+ cells (Figure 16B), whereas 
NOD-Ncf1m1J T cells had a 5-fold increase in CD4+/IL-17A+ expressing cells (Figure 16C).   
The decrease in Th1 cytokine synthesis (IFNγ) from NOD-Ncf1m1J T cells was due to the 
absence of Th1-specific transcription factor expression such as T-bet, Stat4, and Stat1α (Figure 
17A and 17B).  The absence of these key transcription factors in activated NOD-Ncf1m1J T cells 
was associated with the absence of Th1 cytokine synthesis and demonstrates an important role of 
superoxide in skewing T helper responses.  Activation of Stat3, which is necessary for Th17 
lineage commitment (265, 266), was assessed by immunoblot analysis in NOD and NOD-
Ncf1m1J T cells.  Anti-CD3- and anti-CD28-stimulated NOD-Ncf1m1J T cells demonstrated an 
increase in phosphorylated-Stat3 (Y705 and S727) in comparison with NOD T cells after 
stimulation for 48 and 72 hours (Figure 17C-E). 
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Figure 15:  Anti-CD3 and anti-CD28 stimulation of NOD-Ncf1m1J T cells exhibits a decrease in Th1 
cytokine profile concomitant with an increase in Th17 cytokine synthesis.  (A) Immunoblot analysis of p47phox 
expression in negatively selected and purified NOD and NOD-Ncf1m1J T cells.  (B-K) Proliferation and cytokine 
synthesis of purified NOD and NOD-Ncf1m1J T cells (2.5x105 cells) after stimulation with polyclonal Abs for 72 hrs, 
as tested by cytokine-specific ELISAs and Luminex Bio-plex assay for cytokine synthesis.  Proliferation was 
assessed by 3H-TdR incorporation.  Results are representative of three independent experiments done in triplicate. 
n.m., Not measurable 
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Figure 16:  NOD-Ncf1m1J naïve CD4+CD62L+ T cells exhibit a Th17 cytokine profile after polyclonal 
stimulation.  (A) The percentages of splenic naïve (CD62L+CD69-CD44-), effector (CD62L-CD69+CD44+), and 
memory (CD62L-CD69-CD44+) CD4+ T cells were assessed by flow cytometry.  Intracellular cytokine staining of 
(B) CD4+/IFN-γ+ and (C) CD4+/IL-17A+ after 72-h stimulation of purified naïve CD4+CD62L+ T cells from the 
spleen of NOD and NOD-Ncf1m1J mice. 
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Figure 17:  NOD-Ncf1m1J T cells do not express Th1 lineage-specific transcription factors upon 
polyclonal stimulation.  (A) Immunoblot analysis of whole-cell lysates (20 μg protein) of negatively selected 
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purified NOD and NOD-Ncf1m1J T cells after anti-CD3 and anti-CD28 stimulation for 72 h for T-bet, STAT4 and 
STAT1α.  Actin was also probed to confirm equal protein loading on the gels.  STAT3 activation was assessed by 
using phospho-specific STAT3 Abs (Y705 and S727) in an immunoblot analysis of anti-CD3- and anti-CD28-
stimulated NOD and NOD-Ncf1m1J T cells for 48 and 72 h.  Actin was also probed to confirm equal protein loading 
on the gels (C).  Cumulative data from 3 independent experiments employing Image J software (NIH) were used to 
determine the area under the curve values for T-bet, STAT4, STAT1α, P-STAT3 (Y705), P-STAT3 (S727), and 
actin controls. The data are expressed both as the ratio of T-bet, STAT4, or STAT1α to actin or P-STAT3 (Y705) 
and P-STAT3 (S727) to actin (D,E) and as the change after NOD T cell samples were normalized to a value of 1. 
**p<0.01 versus NOD T cells. 
4.4.2 NOD.Ncf1m1J macrophages exhibit a decrease in pro-inflammatory cytokine and 
chemokine synthesis after innate immune activation 
The generation of innate immune-derived proinflammatory cytokines is a redox-sensitive 
process that is highly dependent on the intra- and intercellular signaling capacities of ROS (200, 
202, 207, 267) and necessary for the generation of an efficient Th1 adaptive immune effector 
response  (200, 202, 207, 267-269).   We have previously shown that macrophage NOX effector 
function is required for T1D onset (Fig. 10) and for BDC2.5 CD4+ T cell-mediated diabetes 
induction (Fig. 12B).  To determine whether the Ncf1m1J mutation in NOD-Ncf1m1J bone 
marrow-derived macrophages had an effect on skewing the NOD T cell response from a Th1- to 
a Th17-like phenotype, the innate immune response and the synthesis of proinflammatory 
cytokines from NOD-Ncf1m1J bone marrow-derived macrophages was analyzed after LPS 
stimulation.  To determine if the truncated form of p47phox inherently induced the unfolded 
protein response (UPR) to affect macrophage activation, markers indicative of the UPR (BIP, 
CHOP, and XBP1 splicing) were evaluated by qRT-PCR.  No differences in expression or 
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splicing were observed with control and LPS-stimulated NOD and NOD-Ncf1m1J macrophages 
(data not shown), eliminating endoplasmic reticulum stress as a mechanism for the heightened 
IL-23 production.  NOD-Ncf1m1J macrophages demonstrated decreases of 1.5-fold in TNFα, 3-
fold in IL-1β, 2-fold in IL-12 p70, but no difference in NO2- expression after LPS stimulation in 
comparison to NOD macrophages (Figure 18A-D).  In contrast, LPS-stimulated NOD-Ncf1m1J 
macrophages did exhibit increases in IL-12 p40 (3-fold), G-CSF (2-fold), and IL-6 (2-fold) 
cytokine synthesis as compared with NOD macrophages (Figure 18E-G).  Because IL-12 p40 
levels in NOD-Ncf1m1J macrophages increased 3-fold (Figure 18E), but IL-12 p70 levels 
decreased 2-fold (Figure 18C) in comparison to NOD macrophages, we hypothesize that the 
increased IL-12 p40 subunit may heterodimerize with IL-12 p19 to generate IL-23.  IL-23 
synthesis in LPS-stimulated NOD and NOD-Ncf1m1J macrophages was examined at the protein 
level.  NOD-Ncf1m1J macrophages exhibited a 2-fold increase in IL-23 synthesis by ELISA as 
compared to NOD macrophages (Figure 18H). 
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Figure 18:  NOD.Ncf1m1J macrophages exhibit a skewed Th1 to Th17 pro-inflammatory cytokine 
response after LPS-stimulation.  NOD and NOD.Ncf1m1J bone marrow-derived macrophages were stimulated with 
1 µg/mL LPS for 4 - 24 hours.  Supernatants were harvested and the levels of cytokines and chemokines were 
measured with cytokine-specific ELISAs and with a Luminex Bio-plex cytokine panel (A-H).  Nitrite levels were 
measured using a Greiss assay.  Results are representative of 3 independent experiments done in triplicate. 
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4.4.3 Modulation of superoxide alters Th17 and Th1 cytokine responses after 
immunization 
To determine if a Th17 response in NOD-Ncf1m1J T cells was also occurring in response 
to nominal antigen immunization, NOD and NOD-Ncf1m1J mice were immunized with HEL and 
an antigen-recall assay was performed.  The role and cell source of superoxide were assessed 
using a crisscross HEL antigen-recall assay with purified and negatively selected CD4+ T cell 
and APC LN cellular fractions from both HEL-immunized NOD and NOD-Ncf1m1J mice.  As 
with the anti-CD3/anti-CD28 responses detailed above (Figure 15B-K), in the recall portion of 
the assay when NOD T cells and APC were mixed, they exhibited a Th1 cytokine response, 
whereas the mixture of NOD-Ncf1m1J T cells and APC remained Th17 skewed (Figure 19A-F).  
Interestingly, the development of HEL antigen-specific T cells in vivo with both intrinsic and 
extrinsic source of superoxide, provided stringent commitment towards Th1 memory T cell 
responses that was unaltered when NOX-deficient APC were used in the recall portion of the 
experiment.  However, HEL antigen-specific NOD-Ncf1m1J T cells exhibited both Th1 and Th17 
cytokine responses in the presence or absence of extrinsic superoxide, respectively.  IFNγ and 
IL-2 levels in HEL-specific NOD-Ncf1m1J T cells were restored to NOX-intact levels when NOD 
APC provided an extrinsic source of superoxide (Figure 19A and 19B).  However, in the 
absence of an intrinsic source of NOX, NOD-Ncf1m1J T cells remained high producers of IL-17 
and IL-10 (Figure 19C and 19E).  These data provide evidence that the presence and cellular 
source of superoxide are both key in the type of T helper responses generated during immune 
responses. 
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Figure 19:  NOD-Ncf1m1J mice exhibit both Th17 and Th1 T cell responses after HEL immunization.  
Antigen-recall crisscross assay with negatively selected and purified T cells and APC from the LN of HEL-
immunized NOD and NOD-Ncf1m1J mice.  T cells (2 x 105) and APC (2 x 105) were combined in a crisscross fashion 
with 25 μg HEL and stimulated for 72 h.  Supernatants were collected and cytokine synthesis was measured with 
cytokine-specific ELISAs and a Luminex Bio-plex cytokine panel (A-F).  Results are representative of 3 
independent experiments. 
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4.4.4 NOD and NOD.Ncf1m1J mice do not differ in levels of T Regulatory (Treg) Cells 
Recently, links between Th17 cells and Treg cells have been observed based on their 
requirement of TGF-β synthesis (270) and the established role of this cytokine in Treg 
maturation.  Subsequently, experiments using combinations of IL-6, IL-21, and IL-23 with TGFβ 
established the concept that these cytokines influenced T cell progression toward a Th17 or Treg 
phenotype (271).  Since NOD-Ncf1m1J mice respond to polyclonal and antigenic stimulation with 
a Th17-like cytokine profile (Figures 15, 16, 18, and 19), we further examined if these mice also 
exhibited an increase in Treg cells.  Flow cytometry for Treg cells, as defined by the cell-specific 
markers CD4+CD25+FoxP3+, were compared in NOD-Ncf1m1J and NOD mice.  We did not 
observe a difference in absolute numbers of Treg cells (Figure 20A) nor in the percentage of 
Treg cells relative to splenocytes (Figure 20B) or CD4+ T cells (Figure 9B) between NOD-
Ncf1m1J and NOD mice. 
Figure 20:  NOD mice with Ncf1m1J mutation do not have increased numbers of Treg cells.  (A) The total 
splenocytes and Treg (CD4+CD25+FoxP3+) cell number and (B) percentage of Treg from NOD and NOD-Ncf1m1J 
mice were assessed by flow cytometry.  Total splenocytes were counted on Beckman Coulter (Fullerton, CA) 
counter.  Splenocytes were gated on CD4+CD8-T cells, and CD25+FoxP3+ population was selected to determine 
percentage Treg cells. 
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4.4.5 NOD.Ncf1m1J mice exhibit enhanced sensitivity to MOG35-55-induced Experimental 
Allergic Encephalomyelitis (EAE).  
Th17 cells are essential mediators of autoimmune destruction in multiple sclerosis, 
enriched in the central nervous system-infiltrates (272), and are highly pathogenic upon adoptive 
transfer (273).  It is important to note that previous research has linked mutations in Ncf1 to 
enhanced RA and EAE susceptibility (172, 259), but associations with Ncf1 polymorphisms and 
enhanced Th17 responses have not been correlated.  We therefore tested for differences in EAE 
induction between NOD and NOD-Ncf1m1J mice by employing an immunization strategy with 
myelin oligodendrocyte glycoprotein peptide sequence 35-55 (MOG35-55) that was previously 
demonstrated to elicit a low level of disease incidence in NOD mice (264).  Immunization of 
NOD mice with MOG35-55 resulted in low EAE incidence (3/10; Table 1) with a mean day of 
onset at 62 days.  In contrast, MOG35-55-immunized NOD-Ncf1m1J mice exhibited an extremely 
accelerated disease with a mean onset of 23 days and 100% incidence (11/11; Table 1). 
 
Table 1. NOD-Ncf1m1J mice exhibit enhanced susceptibility to EAE compared to NOD and SJL. 
     EAE   Mean First Day Average Age 
SJL 0/9 0 N/A N/A 
Strain incidencea Severity of Onset     of Onset 
NOD 3/10 0.5 51 62 ± 10 
NOD-Ncf1m1J 11/11b 1.8c 9 23 ± 18 
 
a - EAE was induced as described in the Materials and Methods. 
b - EAE incidence compared to NOD p<0.0001 
c - Mean severity compared to NOD p=0.0018 
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4.5 DISCUSSION 
In our previous studies we have demonstrated the importance of ROS in the pathogenesis 
of T1D (210, 227-229, 232).  Whereas elevated ROS-dissipating enzymes protect against beta 
cell destruction in vitro, the transgenic overexpression of antioxidants in beta cells via the rat 
insulin promoter has been less efficacious in protecting against spontaneous T1D development.  
Previous studies have demonstrated a role of systemic elevation of ROS dissipation (112, 133, 
210, 228, 230, 232) in protection from T1D, yet the effect of altering immune cell ROS 
production in the context of T1D has not been extensively tested.  To address this question, NOD 
mice containing a mutation in Ncf1 (NOD-Ncf1m1J) that prevents the proper assembly of the 
NOX complex, resulting in the absence of superoxide synthesis from stimulated neutrophils (Fig. 
8C), macrophages (Fig. 8E), and T cells (Figure 9A) were generated.  Inhibition of NOX 
activity had a positive impact on diabetes development.  NOD-Ncf1m1J female mice exhibited a 
significant reduction (35% in NOD-Ncf1m1J versus 85% in NOD; P<0.0003) and delay 
(P<0.0001) in autoimmune diabetes development compared to female NOD mice as well as 
reduced insulitis.   
Whereas we have observed reduced autoimmunity in NOD-Ncf1m1J mice, the Ncf1m1J 
allele has been characterized previously in murine models of rheumatoid arthritis (RA) and EAE 
(259).  In addition, deactivating mutations in Ncf1 have been associated with RA in both patients 
as well as in a rat RA model (171, 274).  Likewise, NOD-Ncf1m1J mice also exhibited enhanced 
EAE sensitivity in contrast to the significant reduction in T1D observed in this mutant strain.  
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There are differences between these diseases, with perhaps the most obvious being the inveterate 
Th17 responses associated with both EAE and CIA while data extant have positioned T1D as a 
Th1 mediated disease (255).  Based on our results with the NOD-Ncf1m1J mouse, we 
hypothesized that the divergence in onset of autoimmunity in mice with the Ncf1m1J mutation 
results from alterations in the T helper responses that are indicative of T1D (Th1) versus EAE 
and RA (Th17).  The results contained within demonstrate that superoxide is a key mediator of 
this phenomenon.   
In the absence of superoxide generation, the immune system may compensate for 
impaired neutrophil respiratory burst activity by deviating towards a Th17 phenotype (275).  
Neutrophils are an essential arm of innate immunity and their main effector mechanism in 
response to infection is the initiation of a respiratory burst to generate superoxide.  IL-17 has no 
direct chemotactic activity, but it can induce G-CSF, IL-6, and chemokine expression (276, 277) 
to recruit and activate circulating neutrophils (278).  Loss of ROS-mediated inflammation may 
result in the immune system compensating for this defect by over-expressing signals necessary 
for neutrophil recruitment via IL-17R-signaling.  Recent evidence has demonstrated a role for 
IL-23 in mobilizing neutrophils when host defenses require superoxide production (275).  
Therefore, the overproduction of IL-23 in the NOD-Ncf1m1J system is likely a result of the 
absence of superoxide production.  These findings provide evidence that the loss of superoxide 
synthesis will deviate a Th1-prone immune response towards a Th17 cytokine response. 
It has been well characterized that NOD mice exhibit numerous T cell immunological 
defects such as a strong skewed Th1 cytokine response (279), altered secretion of IL-2 (280), and 
predisposition to heightened IFNγ response compared to C57BL/6 (281).  The enhanced Th1 
cytokine response in NOD mice may be due to chronic redox signaling mediated by an inherent 
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altered redox homeostatic state.  The cytoplasmic and nuclear redox environment of NOD T cells 
may facilitate and enhance Th1 proinflammatory cytokine synthesis that is absent in C57BL/6 T 
cells.  The role of NOX inactivity has conflicting interpretations on the C57BL/6 background.  
Polyclonal-stimulated CD4+ and CD8+ T cells from C57BL/6.p47phox or C57BL/6.gp91phox mice 
demonstrate elevated IFNγ levels and ERK1/2 phosphorylation in contrast to wild-type T cells.  
However, C57BL/6 T cells deficient in the GTP-binding protein Rac2, a co-adapter molecule 
essential for NOX activity (282, 283) exhibited altered T cell activation as evidenced by a 2-3-
fold reduction in IFNγ synthesis and decreased ERK1/2 and p38MAPK activation (284, 285).  
Based on these as well as our previous results, we propose that the introduction of the Ncf1m1J 
mutation in the NOD background lowers the chronic production of ROS, resetting redox 
homeostasis and signaling in this autoimmune prone strain.   
We previously reported that in the absence of a redox-dependent proinflammatory third 
signal consisting of both ROS and proinflammatory cytokines (TNFα, IL-1β, IL-12 p70), 
antigen-specific T cells fail to achieve optimal Th1 effector function (202).  The NOD-Ncf1m1J 
mouse corroborates these observations due to their inherent inability to generate superoxide and 
the resulting altered cytokine profile.  In our current study, we were able to further define and 
characterize the importance of proinflammatory third signal synthesis as it pertains to both Th1 
and Th17 T cell adaptive immune maturation.  Naïve CD4+ T cells from NOD mice elicit a Th1 
response synthesizing increased levels of IFN-γ after polyclonal stimulation.  However NOD-
Ncf1m1J naïve T cells had elevated IL-17 demonstrating a Th17 response when ROS production 
is lacking.  Additionally, NOD mice immunized with HEL generated a memory effector Th1 
cytokine response (IL-12 p70, IFNγ) whereas NOD-Ncf1m1J mice generated a Th17 (IL-17) 
memory effector cytokine response upon secondary challenge with HEL.  In NOX-intact NOD 
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mice whereby an intrinsic (T cell) and extrinsic (APC) source of superoxide is available, antigen-
specific Th1 T cells undergo efficient adaptive immune maturation and effector function.  Upon 
secondary challenge, only a single source of NOX either intrinsically (T cell) or extrinsically 
(APC) will suffice to mediate an efficient Th1 cytokine response.  The memory T cells from the 
NOD mouse remain committed in a Th1 phenotype; alternatively, the lack of extrinsic 
superoxide cannot reprogram these cells.  Interestingly, the cytokine response of NOD-Ncf1m1J T 
cells from the HEL criss-cross antigen-recall assay could be restored to a Th1 phenotype (IL-12 
p70, IFNγ) if an extrinsic source of superoxide (NOD APC) was provided upon secondary 
challenge.  Th17 cells have been noted for their ability to change phenotype.  Highly polarized 
Th17 BDC-2.5 T cells expressing IL-12Rβ2, responded to IL-12 p70, and reverted to a Th1 
phenotype after adoptive transfer in vivo (286).  Further confirming the plasticity of Th17 T cells 
in T1D, Martin-Orozco et al. also demonstrated that Th17-polarized BDC-2.5 T cells converted 
to IFNγ-producing cells and mediate pancreatic beta cell destruction (287).  Th17 T cells may 
have a role in promoting inflammation, but it is the generation of IFNγ and a Th1 effector 
response that is ultimately responsible for autoimmune-mediated beta cell death in T1D. 
The work presented herein demonstrates the significance and importance of innate and 
adaptive immune sources of superoxide to mediate efficient Th1 T cell responses.  Loss of 
intrinsic and extrinsic NOX elicited a novel and skewed Th17 lineage commitment program, 
while suppressing the expression of transcription factors necessary for Th1 T cell development. 
Alternatively, the presence of superoxide appears to drive commitment to Th1.  These in vitro 
responses were confirmed by enhanced susceptibility to EAE in superoxide deficient NOD-
Ncf1m1J mice while NOX-intact NOD mice were polarized to Th1 and developed T1D.   Recent 
reports have documented that Tbx21 and Gata3, genes for Th1 and Th2 lineage commitment, 
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respectively, contain both active and repressive histone modifications in all effector T cell 
subsets that may explain the flexibility of T cells to change phenotypes (288).  Whether 
oxidation of guanine nucleotides to 8-oxo-dG in the promoter elements of Tbx21, Stat4, Rorc, 
and Stat3 can mediate gene silencing and/or expression similar to histone modifications warrants 
further study.  Furthermore, characterizing the importance of ROS in T cell responses may 
provide a novel therapeutic target for the treatment of inflammatory-mediated diseases such as 
T1D, whereas enhancing ROS may skew immune responses that are at the root of multiple 
sclerosis or rheumatoid arthritis. 
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5.0  FINE MAPPING OF ALR-DERIVED SUPPRESSOR OF SUPEROXIDE PRODUCTION 
LOCUS ON CHROMOSOME 3 
5.1 ABSTRACT 
Reactive oxygen species have been proposed to play a role in the pathogenesis of 
autoimmune type 1 diabetes.  Our previous results support this hypothesis by demonstrating that 
reduction of NADPH Oxidase (NOX) activity by either genetic ablation or heightened 
antioxidant activity significantly reduces the development of T1D by altering the function of 
both macrophages and T cells.  We previously linked increased SOD1 activity and decreased 
monocyte ROS with diabetes resistance and decreased autoreactivity in the ALR as well as NOD 
mice congenic for ALR-derived Suppressor of Superoxide Production (Susp) locus.  To 
determine the genetic basis for Susp phenotypes we generated reciprocal congenic mouse strains 
where either the ALR-derived Susp region was introgressed into the NOD genetic background or 
ALR mice carry NOD genome on Chr. 3.  These mice were used to map Susp to a 20 Mbp 
interval.  However, a dearth of informative markers led to the inability to further positionally 
clone the phenotype.  Due to the extreme genetic similarities of ALR and NOD in the Susp 
region on Chr. 3 we initiated an independent cross to fine map the gene responsible for Susp.  
(ALRxCAST) F1 male mice were backcrossed to ALR females to generate 
[ALRx(ALRxCAST)F1]BC1 population.  Genetic linkage analyses determined that only Chr. 3 
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was in linkage disequilibrium for Susp.  Using a total of 464 BC1 mice Susp was localized 
between D3Mit180 (34,405,650 Mbp) and D3Mit223 (34,812,804 Mbp) on Chr. 3.  This 
mapping defines a novel candidate region involved in the regulation of SOD1 activity and 
dimerization stability, resulting in reduced superoxide release via NADPH oxidase activity.  
 
5.2 INTRODUCTION 
ROS production via NADPH Oxidase (NOX) by both antigen presenting cells (APC) 
(153) and T lymphocytes (181) is potentially a major source of free radicals in immune 
signaling.  Genetic ablation of NOX superoxide production in an NOD background provides 
significant protection from advancing insulitis and diabetes onset (184).  As well, antioxidant 
regulation of free radical production has been associated with T1D resistance (202, 207, 208, 
210).  Previous genetic mapping studies using T1D-prone NOD with T1D-resistant ALR mice 
linked resistance against spontaneous autoimmune diabetes, reduced oxidative burst from 
neutrophils and macrophages, as well as elevated Superoxide Dismutase 1 (SOD1) activity to the 
Suppressor of Superoxide Production (Susp) locus on Chr. 3 (112, 230).  Congenic replacement 
of Chr. 3 Susp locus in the NOD provided 100% protection from T1D and was associated with 
decreased autoreactivity of T lymphocytes (Chapter 2).  This suggests that Susp regulation of 
SOD1 activity was modifying T1D susceptibility. 
The SOD1 enzyme is highly conserved and is ubiquitously expressed (289).  Post-
translational modifications of SOD1 are essential for enzyme maturation and activation (289-
292).  Foremost, the binding of zinc and the incorporation of copper facilitated by the copper 
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chaperone for SOD1 (CCS) are required.  Copper loading is accomplished via oxygen-dependent 
disulfide isomerization, producing disulfide-oxidized SOD1 subunits (293, 294).  Two oxidized 
SOD1 subunits homodimerize to form enzymatically active SOD1 (292, 295).  Metal 
incorporation and dimerization are tightly regulated, however the mechanism controlling these 
activities are not fully defined.  As SOD1 facilitates the dismutation of superoxide to hydrogen 
peroxide, this scavenging is important to alleviate redox stress during and after inflammatory 
processes (234, 289, 296).  In addition to free radical scavenging, recent studies suggest SOD1 
interacts with NOX subunits to regulate superoxide production (297).  Characterization of 
increased SOD1 activity and stability as well as reduced superoxide release in the ALR suggests 
a novel interaction mediated by a gene candidate for Susp is facilitating a post-translational 
modification of SOD1.   
To determine the genetic basis for increased SOD1 activity and stability as well as 
reduced NOX, (ALRxCAST) F1 male mice were backcrossed to ALR females to generate 
[ALRx(ALRxCAST)F1]BC1 population.  A cohort of 40 BC1 mice, as well as 16 BC1 mice 
with recombinations on Chr. 3 was assessed for SOD1 activity and respiratory burst.  Coupling 
phenotypic characterization with genotypic profiling analyses determined only Chr. 3 was in 
linkage disequilibrium.  High resolution fine mapping localized ALR-derived Susp locus 
between D3Mit180 (34,405,650 Mbp) and D3Mit223 (34,812,804 Mbp) on Chr. 3.  To date, this 
interval contains one known gene, Sox2, three predicted genes, and one microRNA, Mir1897.  
Evaluating the Susp interval and these candidates may define allelic or expression differences 
unique to the ALR that directly or indirectly regulate SOD1 dimerization.  This mapping 
potentially defines a novel candidate involved in the regulation of SOD1 activity and NOX 
function. 
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5.3 METHODS 
5.3.1 Animals 
The ALR-derived Susp locus was congenically introgressed into the NOD genome as 
well as introduction of NOD Chr. 3 region to ALR.  NOD mice were mated with male ALR 
mice, and the subsequent F1 progeny were backcrossed to NOD.  Likewise, Fl progeny from 
ALR female to NOD male matings were backcross to ALR.  Selection for either ALR or NOD 
contributing genome on Chr. 3 and eliminating contamination elsewhere on the genome was 
achieved through PCR amplification of 76 informative microsatellite primers spanning all 
Chromosomes and 6 microsatellite primers on Chr. 3.  Mice were backcrossed for 10 
generations, followed by intercrossing to select NOD mice with ALR homozygous Susp locus 
(NOD-Susp) or ALR mice homozygous for NOD genome on Chr. 3 (ALR.NODc3).  Mice with 
various recombinations on Chr. 3 were used for fine mapping analysis. 
ALR/LtJ, NOD/ShiLtJ, NOD-Susp, ALR.NODc3, as well as [ALRxNOD]F1 hybrid mice 
were bred and housed in the University of Florida facility under specific pathogen-free 
conditions.  CAST/EiJ were purchased from The Jackson Laboratory (Bar Harbor, ME) and were 
outcrossed with ALR/LtJ in our facility.  [ALRxCAST]F1 hybrid progeny were backcrossed to 
ALR to generate a first backcross (BC1) generation.  All mice were housed in specific pathogen-
free facilities and approved by the Institution Animal Care and Use Committee at the University 
of Florida. 
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5.3.2 Materials 
Dihydrorhodamine 123 (DHR123) was purchased from Invitrogen (Carlsbad, CA).  
Superoxide Dismutase activity assay kit was purchased from Cayman Chemical (Chantilly, 
Virginia).  All DNA oligonucleotides were obtained from Integrated DNA Technologies, Inc. 
(Coralville, Iowa).  Histopaque-1119 was obtained from Sigma-Aldrich (St. Loius, MO).  
 
5.3.3 Assessment of SOD1 activity  
Liver and bone marrow homogenates were prepared in 20 mM HEPES buffer (pH 7.2) 
with 1 mM EGTA, 210 mM mannitol and 70 mM Sucrose.  Protein content was determined 
using Pierce BCA Protein Assay Kit (Thermo Scientific).  SOD1 was extracted using 
ethanol:chloroform (62.5/37.5 v/v).  After centrifugation at 3000 x g for 5 min, the aqueous layer 
contained SOD1 was collected.  SOD1 activity was measured with Superoxide Dismutase Assay 
Kit (Cayman Chemical) following manufacturer’s protocol. 
5.3.4 Flow cytometric analysis of oxidative burst 
Neutrophil and macrophage superoxide production were assayed using FACS as 
previously described (230).  Briefly, bone marrow was isolated and purified using a Histopaque-
1119 gradient.  Cells were labeled with PerCpCy5.5-labeled anti-Ly6g (Gr1) and APC-labeled 
anti-CD11b and then loaded with Dihydrorhodamine 123 (DHR 123) for 5 minutes at 37°C.  
Cells were subjected to flow cytometry prior to stimulation, and then at 5 min intervals after 98 
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nM PMA stimulation.  The ROS driven conversion of DHR 123 to rhodamine was measured 
using a BD Fortessa and were analyzed with FACSDiva software (BD Biosciences). 
5.3.5 Genome Wide Scan using single nucleotide polymorphisms 
Backcross mice generated from the mating of (ALRxCAST) F1 to ALR were used for 
phenotypic analysis of oxidative burst and SOD1 activity as well as genotypic analysis.  
Genomic DNA was prepared from kidney and genotyped for 73 SNPs spanning all chromosomes 
by Kbiosciences (Table 2).  High resolution coverage of Chr. 3 was obtained by PCR 
amplification of 10 microsatellite markers (Table 2).  Chi square values were calculated using 
JMP software and considered significant with p<0.001. 
5.3.6 Candidate gene expression analysis 
RNA was isolated from bone marrow and live lysates with TRIzol and cDNA prepared 
by M-MLV reverse transcriptase kit (Invitrogen).  PCR amplification was performed with the 
following primers: Gm3143 forward 5’-TCACAGGAAAGATGGCAGTCA-3’, reverse 5’- 
TTGGGCCACAACAGTGAAAG-3’; Gm6282 forward 5’-ATCCAGTCGCTCAGGTGCT-3’, 
reverse 5’-TGGGAGATGCTGTTCCAAAGT-3’; Gm7723 forward 5’-
GAGCAGGGAAAGTTTGGAGC-3’, Gm7723 5’-GGTGAAGAGGGGTTGGTGAG-3’; and 
Sox2 forward 5’-CGAACTGGAGAAGGGGAGAG-3’, reverse 5’-
AAGCGTTAATTTGGATGGGA-3’.  Amplification products were separated on a 4% agarose 
gel and visualized with ethidium bromide. 
 116 
5.3.7 Cytochrome c measurement of oxidative burst 
Bone marrow was collected from age-matched female mice and red blood cells were 
removed on a Histopaque-1119 gradient as previously described (230).  Cells (105) were 
pretreated with 2 mM KCN or HBSS for 15 min at room temperature, transferred to HBSS 
containing 145 μM cytochrome C, and were stimulated with PMA (98 nM) at 37°C.  Reduction 
of cytochrome C was measured at 550 nm at 1 min intervals for 45 min.  The maximum rate of 
reduction was calculated by linear regression analysis.  Purified SOD1 (0.5 U/mL) was used to 
confirm specificity of superoxide production. 
5.3.8 Statistics 
GraphPad Prism (GraphPad Software, Inc, (La Jolla, CA)] was used for calculating 
statistical differences.  Significance between mean values was determined using the Student’s t 
test or One-way ANOVA test, with p < 0.05 considered significant.  Kaplan-Meier survival 
analysis was used to evaluate diabetes onset. 
5.4 RESULTS 
5.4.1 Genetic analysis and fine mapping of Susp locus on Chr. 3. 
Previous segregation analysis localized reduced superoxide production in the ALR to a 
locus on Chr. 3 termed Susp (112, 230), controlling increased SOD1 activity and decreased NOX 
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function.  This locus overlapped with an independently mapped ALR-derived T1D protective 
locus, suggesting Susp may contribute to diabetes resistance by modifying ROS production 
(230).  To evaluate the role of the Chr. 3 locus, NOD-Susp mice were generated by introducing 
ALR Chr. 3 genome into the NOD background (NOD-Susp), as well as the reciprocal congenic 
by introgressing of NOD Chr. 3 genome to the ALR (ALR.NODc3).  During the development of 
the congenic mice progeny were screened on Chr. 3 to map recombinations, followed by 
phenotypic analyses of oxidative burst and SOD1 activity.  Coupling phenotypic profile (Fig. 
21A-B, showing most informative mice) with genotyping information a physical location 
between microsatellite markers D3Mit167 (32.1 Mbp) and D3Mit64 (49.9 Mbp) was defined 
(Fig. 21C).  Further recombination boundary discrimination was limited due to the lack of 
additional informative microsatellites.  In fact, in the region on Chr. 3 NOD and ALR have few, 
if any, polymorphisms.  To identify informative polymorphisms comparing ALR to NOD the Jax 
Diversity array was run.  Analyses did not provide additional polymorphisms comparing NOD 
and ALR (Fig. 22) and served to confirm the haploidentity throughout this region on Chr. 3.  
However, the diversity array analysis comparing ALR to CAST identified high degree of genetic 
diversity (Fig. 22).  CAST strain also elicits a robust oxidative burst and demonstrates low SOD1 
activity compared to the ALR (Fig. 23).  Therefore, to obtain high resolution fine mapping, the 
ALR was mated to CAST, followed by backcrossing F1 progeny to ALR. 
Genome-wide linkage analysis was performed using a cohort of 40 BC1 mice.  Backcross 
mice were assessed for oxidative burst and SOD1 activity compared to parental controls.  
Genomic DNA was analyzed for 73 informative SNPs spanning all chromosomes, with only Chr. 
3 in linkage disequilibrium with Susp (Table 2), with the peak at D3Mit168 (Fig. 24).  An 
additional 490 backcross mice were screened for recombinations on Chr. 3, identifying 16 mice 
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that exhibited meioses within the Susp interval.  Genotypic profiling and phenotypic analyses of 
these mice allowed for high resolution mapping on Chr. 3, localizing Susp to the 407,297 bp 
region between D3Mit180 (34.4 Mbp) and D3Mit223 (34.81 Mbp). 
 
 
Figure 21:  Fine Mapping of NOD-Susp and ALR.NODc3 recombinant mice.  Evaluation of 
phenotypic profile of (A) liver-homogenate SOD1 activity and (B) macrophage respiratory burst after PMA 
stimulation.  Superoxide production was measured by monitoring the conversion of DHR123 via flow cytometry.  
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Mean fluorescence intensity (MFI) at 30 min post-PMA is normalized to NOD as 100%.  (C) Genotyping of 
microsatellite markers on Chr. 3 defines the physical location of Susp.  Represented are the most informative mice, 
defining the boundaries of the physical location.  Regions of unknown genetic inheritance in grey. 
 
 
Figure 22: Diversity array of Single Nucleotide Polymorphisms (SNP) across Chr. 3 comparing ALR 
to CAST and NOD.  SNPs determined as the measured intensity difference (y-axis) in nucleotide base at a given 
position across Chr. 3 (x-axis), with a difference above 1 (blue line) considered as polymorphic. 
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Figure 23: Phenotypic profile of CAST mice.  (A) Liver SOD1 activity of CAST compared to NOD and 
ALR.  (B) Superoxide production was measured by monitoring the conversion of DHR123 via flow cytometry.  
Mean fluorescence intensity at 30 min post PMA is normalized to NOD as 100%.  
 
Table 2:  Linkage of SNP and microsatellites in [ALRx(ALRxCAST)F1]BC1 mice.  Mice were 
phenotypes for SOD1 activity and NOX respiratory burst.  Mice were characterized as ALR-like with high SOD1 
activity (>300U/mg protein) and low NOX (MFI <50% of control) or CAST-like.  All mice exhibited the inverse 
correlation of SOD1 and NOX activities.  Marker positions in base pairs were obtained from The Jackson 
Laboratory Mouse Genome Informatics Database.   
    
BC1 High 
SOD/Low 
NOX 
BC1 Low 
SOD/High 
NOX 
P 
value Χ
2 
Locus base pair R FI R FI 
01-008110094-M 8,110,094 12 8 9 15 0.1353 2.231 
01-062173915-M 62,173,915 10 11 10 16 0.5279 0.398 
01-114000704-M 114,000,704 11 10 9 17 0.2202 1.503 
01-147325075-M 147,325,075 12 9 6 16 0.0454 4.002 
01-193173300-M 193,173,300 14 6 11 12 0.1389 2.19 
02-025336678-N 25,336,678 9 12 13 12 0.536 0.383 
02-080232231-M 80,232,231 12 9 11 15 0.311 1.027 
02-119060027-N 119,060,027 16 6 11 14 0.025 5.022 
02-172943830-M 172,943,830 12 8 11 14 0.2848 1.144 
03-009298864-M 9,298,864 18 9 2 23 0.0001 20.983 
D3Mit167 32,170,748 22 5 0 27 0.0001 47.122 
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D3Mit240 32,529,024 23 4 0 23 0.0001 51.018 
D3Mit181 32,965,530 26 1 0 24 0.0001 66.232 
03-034069633-M 34,069,633 25 1 0 26 0.0001 66.232 
D3Mit180 34,405,650 25 1 0 27 0.0001 66.232 
D3Mit168 34,539,623 27 0 0 27 0.0001 74.86 
D3Mit223 34,812,804 27 0 1 26 0.0001 66.232 
03-036328929-N 36,328,929 24 0 2 24 0.0001 60.305 
D3Nds6 37,018,998 26 1 1 25 0.0001 51.973 
D3Nds43   25 2 2 21 0.0001 46.342 
D3Mit295 38,827,463 23 4 4 19 0.0001 29.556 
D3Mit307 39,437,974 22 5 4 23 0.0001 26.259 
03-043110442-M 43,110,442 20 6 3 23 0.0001 24.706 
D3Mit65 50,488,800 19 8 5 22 0.0001 15.501 
03-074327277-M 74,327,277 18 8 4 22 0.0001 16.43 
03-100489838-M 100,489,838 18 8 8 18 0.005 7.894 
03-131286062-N 131,286,062 15 11 10 16 0.1639 1.938 
03-155372777-M 155,372,777 16 10 16 10 1 0 
04-014657884-N 14,657,884 10 11 13 13 0.871 0.026 
04-053894587-M 53,894,587 7 14 12 13 0.3125 1.02 
04-103038694-M 103,038,694 6 15 11 15 0.3273 0.96 
04-151168886-M 151,168,886 8 13 15 11 0.1799 1.799 
05-113995253-M 113,995,253 11 10 10 16 0.3396 0.912 
05-125054661-M 125,054,661 13 8 12 14 0.2806 1.164 
05-137165117-N 137,165,117 14 7 12 14 0.1573 2 
05-150172420-M 150,172,420 13 8 11 15 0.1799 1.799 
06-006933444-M 6,933,444 12 9 10 15 0.2453 1.35 
06-064751205-M 64,751,205 13 7 13 13 0.3071 1.043 
06-109051116-M 109,051,116 10 10 16 10 0.4339 0.612 
07-006208019-M 6,208,019 11 10 16 11 0.6338 0.227 
07-043206744-N 43,206,744 14 7 13 11 0.3918 0.733 
07-093235239-M 93,235,239 12 9 16 9 0.6352 0.225 
07-135024189-M 135,024,189 12 8 14 11 0.7871 0.073 
08-007750917-N 7,750,917 9 12 9 17 0.5636 0.333 
D8Mit293 148,932,688         0.35 0.873 
08-088042210-M 88,042,210 10 11 8 17 0.2794 1.17 
08-126038064-N 126,038,064 9 12 13 12 0.536 0.383 
09-003938578-M 3,938,578 9 12 12 14 0.8211 0.051 
09-052894456-M 52,894,456 9 12 10 16 0.7602 0.093 
09-115037423-M 115,037,423 13 8 11 14 0.2244 1.476 
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10-018064293-M 18,064,293 13 8 13 13 0.4134 0.669 
10-089875395-N 89,875,395 13 8 13 12 0.499 0.457 
10-128874353-N 128,874,353 9 12 11 14 0.9379 0.006 
11-011378766-M 11,378,766 10 10 10 16 0.3396 0.912 
11-066278669-N 66,278,669 9 12 16 10 0.2009 1.636 
11-115546745-M 115,546,745 10 10 12 12 1 0 
12-009581325-M 9,581,325 11 8 13 13 0.5997 0.276 
12-053361254-M 53,361,254 13 8 11 11 0.4313 0.619 
12-107541607-M 107,541,607 10 9 12 13 0.7608 0.093 
13-009820324-M 9,820,324 9 10 8 16 0.35 0.873 
13-062804732-M 62,804,732 10 10 8 19 0.1556 2.016 
13-105849719-M 105,849,719 11 9 11 14 0.4629 0.539 
14-013002953-M 13,002,953 13 8 10 15 0.1372 2.209 
14-062668837-N 62,668,837 9 12 14 12 0.4531 0.563 
14-112544301-N 112,544,301 9 12 14 11 0.3738 0.791 
15-006448712-N 6,448,712 11 9 13 13 0.7364 0.113 
15-055111506-N 55,111,506 12 9 13 13 0.6253 0.238 
15-103221933-M 103,221,933 11 10 11 14 0.5707 0.322 
16-005644892-N 5,644,892 10 11 12 14 0.9203 0.01 
16-031980782-C 31,980,782 10 11 10 15 0.6036 0.27 
16-090091107-C 90,091,107 9 12 10 16 0.7602 0.093 
16-091028945-C 91,028,945 9 12 9 17 0.5636 0.333 
16-096070057-C 96,070,057 9 12 10 16 0.5636 0.333 
17-004147924-M 4,147,924 10 11 12 13 0.9794 0.001 
17-031242489-M 31,242,489 11 10 12 14 0.6711 0.18 
17-034146583-M 34,146,583 10 11 12 14 0.9203 0.01 
17-092673068-N 92,673,068 12 9 14 12 0.8211 0.051 
18-006845916-M 6,845,916 9 12 13 13 0.6253 0.238 
18-063800148-N 63,800,148 8 13 14 12 0.2806 1.164 
19-007376322-N 7,376,322 8 13 17 10 0.0856 2.954 
19-057152618-M 57,152,618 12 9 14 12 0.8211 0.051 
X-035414447-M 35,414,447 11 8 13 11 0.8068 0.06 
X-121648292-M 121,648,292 10 11 14 11 0.8061 0.06 
        
Χ2 values are considered significant at p<0.001    
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Figure 24:  Map position of ALR-derived Susp locus on Chr. 3.  Genetic linkage analysis using 
[(ALRxCAST)F1xALR]BC1 mice assessed for SOD1 activity and respiratory burst.  Linkage was determined with 
56 BC1 mice using χ2 analysis (JMP, Cary, NC) with P-value less than 0.001 considered significant. 
5.4.2 Evaluation of genes within the Susp interval 
High resolution fine mapping localized Susp between markers D3Mit180 (34,405,650 
Mbp) and D3Mit223 (34,812,804 Mbp) on Chr. 3 (Table 2) with peak Chi square value at 
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D3Mit168.  PCR was performed to determine liver and bone marrow expression of the known 
gene, Sox2, and predicted genes, Gm3143, Gm6282, and Gm7723.  Neither Sox2 nor the 
predicted genes were expressed in either tissue from NOD and ALR (Data not shown), 
eliminating these as potential candidates.  Contained within this interval is a microRNA 
Mir1897, which is currently being evaluated for polymorphisms unique to ALR. 
5.4.3 Assessment of respiratory burst in SOD-/- mice 
Previous reports suggest a regulatory role for SOD1 by binding to NOX complex 
subunits (297).  Measuring superoxide release in bone marrow from B6-SOD1-/- knock out mice 
demonstrated a robust respiratory burst after PMA stimulation, even higher than full inhibition of 
SOD1 with KCN in B6 bone marrow (Fig. 25).  These data suggest that the physical presence of 
SOD1, even without dismutation activity, regulates NOX function. 
 
Figure 25:  Superoxide release after KCN inhibition of SOD1 and PMA stimulation.  Bone marrow 
cells from NOD, ALR, B6 and B6-SOD-/- mice were pretreated with 2 mM KCN to inhibit SOD1 activity.  Cells 
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were stimulated with PMA and the release of superoxide was measured by rate cytochrome c reduction.  Purified 
SOD1 was added to confirm specificity of superoxide production. 
5.5 DISCUSSION 
Previous segregation analysis localized reduced superoxide production in the ALR to a 
locus on Chr. 3 termed Susp (230).  This locus overlapped with an independently mapped ALR-
derived T1D protective locus, suggesting Susp may contribute to diabetes resistance in the ALR.  
Introduction of the ALR-derived Susp locus to the NOD background provided full protection 
from T1D and insulitis (Fig. 4) and a loss of diabetogenic reactivity of NOD-Susp CD4+ T cells 
in susceptible hosts (Fig. 5C).  The reduction in neutrophil, macrophage, and CD4+ T cell ROS 
production after stimulation is associated with increased activity of SOD1 (Fig. 6). 
We have previously shown that reduction of superoxide production by macrophages and 
T cells has a profound impact on cytokine synthesis and T lymphocyte lineage commitment 
(184, 202).  Likewise, antioxidant regulation of free radicals also modifies macrophage and T 
cell reactivity (208, 210).  In order to define the modification to SOD1 and the resulting 
modulation of immune effector function inherent to ALR, genome wide analyses were 
performed to fine map Susp.  Through the use of [ALRx(ALRxCAST)F1]BC1 mice ALR-
derived Susp locus was mapped between D3Mit180 (34,405,650 Mbp) and D3Mit223 
(34,812,804 Mbp) on Chr. 3 (Table 2) with peak Chi square value at D3Mit168.  Described to 
date in this region is one known gene, Sox2, three predicted genes, and one microRNA, Mir1897.  
Sox2 and the three predicted genes were not expressed in liver or bone marrow cDNA as 
determined by PCR, eliminating these as candidates.  Evaluating the microRNA and further 
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sequencing of the Susp interval may define allelic or expression differences unique to the ALR 
that directly or indirectly regulate SOD1 dimerization. 
Evaluation of SOD1 from ALR did not define any polymorphisms in cDNA sequence, 
expression, or protein content (Fig. 2) compared to control strains that would account for 
increased activity.  ALR and NOD-Susp SOD1 dimer activity under reducing conditions was 
enhanced (Fig. 2), suggesting a post-translational modification was increasing enzyme stability.  
Inhibiting SOD1 with KCN was able to restore superoxide release after stimulation (Fig. 3B); 
confirming elevated dismutation modified immune cell effector function.  However, ALR and 
NOD-Susp superoxide release after KCN inhibition of SOD1 was not restored to the same levels 
as NOD, suggesting further regulation of NOX activity.  Recent data suggests that SOD1 
interactions with NOX complex subunits, including Rac1, provide physical control of superoxide 
production (297).  Measuring superoxide release in bone marrow from B6-SOD1-/- knock out 
mice demonstrated a robust respiratory burst after PMA stimulation, even higher than full 
inhibition of SOD1 with KCN in B6 bone marrow (Fig. 25).  These data suggest that the 
physical presence of SOD1, even without dismutation activity, regulates NOX function. 
Enhanced stability of ALR SOD1 dimer may also provide enhanced physical association 
with NOX-regulating compounds.  There are several reports that describe a regulatory role of 
various proteins contributing to SOD1 binding and stability (138, 298, 299).  Post-translational 
modifications are required for the assembly and maturation of active SOD1 enzyme, including 
incorporation of zinc and copper (138).  While regulation of copper loading by the copper 
chaperone for SOD1 (CCS) (298) is described, mechanisms regulating dimerization are not well 
defined.  Recently, a novel interaction of copper metabolism Murr1 domain containing 1 
(COMMD1) with SOD1 was associated with regulation of enzyme maturation and dissipation 
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(299).  A candidate gene or microRNA in the Susp interval may directly or indirectly modify 
dimer stabilization and binding, resulting in increased free radical scavenging and regulation of 
NOX.  The alterations in redox balance may then modify free radical signaling and immune cell 
activity during inflammatory processes (Fig 26).  
 
 
Figure 26:  Schematic of proposed model of Susp contributions to free radical dissipation, redox 
signaling, and immune cell function. 
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6.0  CONCLUSION AND SIGNIFICANCE 
Type 1A diabetes (T1D) is an autoimmune disease typically diagnosed in children and 
adolescents.  According to the American Diabetes Association National Fact Sheet (2007), 
approximately 1% of the US population has T1D, with an incidence that is increasing at a rate of 
3% per year.  Despite advances in insulin-replacement therapy and blood glucose monitoring, 
there is no cure for T1D.  Additionally, patients are at increased risk of severe complications 
associated with poor glycemic control, including cardiovascular disease, blindness, neuropathy, 
and nephropathy.   
 While previous reports suggested that antioxidant scavenging protected beta cells against 
free radical-mediated damage, the data presented here suggest that modulation of ROS had 
profound effects on the activity of autoimmune effectors.  Specifically, the work herein describes 
a critical role for ROS signaling in the development of proinflammatory T lymphocyte 
responses.  Two models were used to define the role of leukocyte-produced superoxide in the 
development of T1D: the NOD-Ncf1m1J, with a genetic ablation of NOX function, and the NOD-
Susp, congenic for the ALR-derived allele associated with increased free radical scavenging. 
In both models, the inhibition of NOX function significantly reduced the development of 
T1D.  This was coupled with reduced severity of insulitic infiltration, suggesting that ROS 
production may play a role in the migration and/or accumulation of autoreactive effectors.  
Despite previous reports that antioxidant therapy could protect beta cells from ROS-mediated 
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damage in vitro, the transgenic over-expression of antioxidants in beta cells via the rat insulin 
promoter has been less efficacious in preventing spontaneous T1D development (225, 237, 238).  
Rather, systemic elevation of antioxidants has more consistent results for protection of islets 
from damage (202, 210, 232, 239).  Concordantly, islets from NOD-Susp congenic mice did not 
exhibit full protection from proinflammatory mediators, suggesting that elevated SOD1 in the 
pancreata was not providing the majority of T1D resistance.  When assessing immune function, 
T cells from NOD-Susp mice failed to induce T1D in a susceptible host.  Likewise, splenocytes 
and purified T cells from NOD-Ncf1m1Jmice exhibited delayed transfer of T1D.  Taken together, 
these data highlight an essential role for ROS production in the development of efficient T 
lymphocyte autoreactive effector function.  
Characterization of NOD-Ncf1m1J macrophage and T cell responses identified a skewed 
phenotype favoring Th17 lineage commitment, as opposed to the proinflammatory Th1 profile 
typical of NOD.  Th1 associated cytokine synthesis could be recovered as long as either APC or 
T cells were competent ROS producers during antigen recall.  Interestingly, NOX-deficient T 
cells maintained elevated IL-17 and IL-10 production, suggesting in vivo imprinting for cytokine 
production.  These data suggest that ROS may provide transcriptional regulation during T cell 
development and activation.  Preliminary data with ALR splenocytes suggest a similar skewing 
of the immune response.  Now that the Susp locus has been mapped to a ~407,000 bp interval, 
production of congenic mice based on this region can identify a candidate gene and mechanism 
accounting for the increased SOD1 activity and stability.  Additionally, the role of Susp in 
modifying T cell effector function can be defined.  These data suggest that redox-sensitive 
genetic regulatory elements are critical in the development of T helper lineage commitment.  
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Further identification of these targets may define mechanisms important in the aberrant immune 
response in mouse and human autoimmune conditions. 
The primary goals of ongoing research of T1D in the NOD mouse are to determine 
factors that contribute to and drive autoimmune pathogenesis, to develop ways to intervene 
and/or reverse the course of beta cell loss and ultimately to apply these therapeutics to cure and 
prevent human T1D.  Therapies to modulate tolerance to autoantigens, such as insulin, have been 
tested in NOD (300-302) and human patients (303).  Treatments to modulate the immune 
response through the administration of anti-CD3 in mice (304-307) and humans (308), as well as 
anti-thymocyte globulin (ATG) (309) have also been investigated.  While such treatments are 
effective in the mouse, responses in human patients have so far been underwhelming (308).  This 
demonstrates the need for improved translation of dosing and timing requirements from mouse to 
human patients.  Additionally, the identification and evaluation of subgroups to determine which 
regimens are the most successful stratified by biological markers and disease state may 
positively affect trial outcomes. 
Much of the work in the NOD demonstrates that diabetes is a multigenic, multifaceted 
disease; there are most likely many genetic and immunological dysfunctions that, when 
combined with environmental factors, influence disease pathogenesis.  Investigation of T cell 
activation demonstrates that many conditions can affect activation status, including redox status.  
Cytokine production and mechanisms of killing involve multiple pathways with overlap and 
redundancy, suggesting that therapeutics targeting these products will require a combination of 
approaches.  It is important to note that there are hundreds of therapies that can prevent and 
dozens that can reverse T1D in the NOD (reviewed in (95, 303)).  Failures in translation may 
prove useful in exposing both the similarities and differences between diabetes in mouse and 
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man.  These observations also reinforce the need to standardize characterization of disease state, 
assessment of biological targets, and outcome of therapies in the NOD.  Timing and dosing 
thresholds for effective prevention or reversal are critical.  Similarly, standardized definitions of 
biomarker positivity, such as autoantibody titer, C-peptide, and markers of immune modulation 
during the course of treatment are needed to assist researchers in comparing successes and 
failures within and between laboratories and to assist in the translation of these data to human 
T1D trials.  As the pathology of many diseases in humans, particularly autoimmune diabetes, is 
multifaceted and complex, therapies will most likely require a combined approach.  Clinical 
trials are underway to assess the safety and effectiveness of immune suppression and alteration 
of APC function, including tolerizing DC populations and depletion of B cells with rituximab.  
However, immune suppression is far from ideal, as it is associated with various risks and 
complications.  Defining redox-sensitive targets that modulate immune reactivity may provide 
further methods of regulating T cell reactivity.  Therefore, combined therapy may provide 
sufficient tailoring of the immune response without rigorous immunosuppression.  
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